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Synopsis 
Leishmaniasis, the disease caused by a genus of Leishmania protozoan parasite, is 
the second largest parasitic killer in the world (after malaria) responsible for an 
estimated 500,000 cases and 60,000 deaths each year worldwide. Visceral 
leishmaniasis infections (i.e., affecting internal organs like liver and spleen) are more 
complicated to diagnose due to the lack of visible symptoms. Current tests of the 
disease look for antibodies against the parasite, but these antibodies are expressed 
long after the infection. It has been found the Leishmania parasite excretes a unique 
phosphoglycan repeat unit: 
O
HO
HO
HO
n = 4-32
O
OH
O
O
P
O O
O
HO
HO
...-6-β-D-Galp-(1→4)-α-D-Manp-(1-OPO2H-...  
 
By looking for this repeat unit, the diagnostic test will be checking for an active 
infection in the patient. It has been found that there are monoclonal antibodies to 
detect this uniquely excreted phosphoglycan. This provides a basis for a test kit, the 
biomarker (i.e., the phosphoglycan repeats), and the way to detect the biomarker. 
For the construction of a dipstick style test or an ELISA format assay, a chemically 
synthesised repeat unit phosphoglycan is needed to act as a positive control in a 
dipstick test or as a known comparison in an ELISA.  
 
The synthetic phosphoglycan structure must also be anchored to a solid surface for 
testing. Biotin will be used as the anchor. It has shown many different applications in 
biotechnology and its very high affinity to the avidin proteins make it very useful. A 
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6-aminohexanol spacer arm (i.e., a linker) will also be included in the synthetic 
structures. 
After original attempts to introduce the biotin moiety to the repeat unit at the D-
mannose 1-phosphate, it was decided to change the strategy and integrate the 
biotin moiety via linker and phosphate at the D-galactose unit. This meant 
performing chain elongation from the reducing end, with the first disaccharide unit 
being capped at the D-mannose anomeric position with a methyl group. Below are 
examples of the targeted biotinylated phosphoglycan structures, which have been 
prepared in this project. 
 
     
 
All three prepared biotinylated phosphoglycan structures were tested in ELISA assay 
using monoclonal IgG antibodies that recognises the repeat unit structure. They 
showed different activities in terms of antibody recognition and binding. The largest 
compound containing three repeats demonstrated the strongest signal. This positive 
result provides a foundation for novel assay formations and further immunological 
work. 
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1. INTRODUCTION 
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1.1 Biological Introduction 
 
1.1.1 Neglected Parasitic Diseases 
 
Diseases such as malaria, leishmaniasis, African sleeping sickness (or African 
trypanosomiasis) and Chagas disease (or American trypanosomiasis) are all caused 
by insect-transmitted parasites. These diseases infect millions of people around the 
world and millions more are at risk of infection. Figure 1 gives an overview of the 
diseases their causative agents and the number of cases reported. 
 
 
Figure 1 – Parasitic protozoan diseases [1] 
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1.1.2 Leishmaniasis 
 
The origins of Leishmaniasis are unknown [2]. There are records of lesions similar to 
the ones caused by leishmaniasis on tablets from the library of Ashurbanipal, King of 
Syria, from the 7thcentury BC. These are thought to be derived from earlier texts 
from 1500 to 2500 BC[3]. It was first described in the modern era by Peter Borovsky, a 
Russian military surgeon who was conducting research into the etiology of an 
oriental sore in Tashkent, Uzbekistan. In 1898, he published the first accurate 
description of the causative agent, the parasite’s relation to the host tissues and 
even referred to it as a protozoa. However, his results were published in a Russian 
journal with low circulation so were not internationally acknowledged during his 
lifetime[4]. In 1901 William Boog Leishman and Charles Donovan identified certain 
organisms in smears taken from the spleen of a patient who had died from “dum-
dum fever” and called them trypanosomatids, which came to be known as Leishman-
Donovan bodies[5][6]. 
 
1.1.2.1 Leishmaniasis Epidemiology 
 
Leishmaniasis is a poverty related disease affecting the poorest people who are 
suffering from malnutrition, are being displaced and have a weakened immune 
system. Leishmaniasis is also related to environmental changes such as 
19 
 
deforestation, dam building and new irrigation schemes causing migration of non-
immune people into endemic areas[7][8]. The disease is prevalent and endemic in the 
tropics and sub-tropics covering large areas of Bangladesh, Pakistan, India, Africa, 
the Middle East, South and Central America and along the Mediterranean. 
 
 
 
Figure 2- Geographical distribution of leishmaniasis (light blue) and co-infection with HIV (dark blue) 
[1] 
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1.1.2.2 Disease Burden  
Recently the public health impact of leishmaniasis has been re-assessed and it was 
found that previous estimates were very low compared to the actual burden of the 
disease. It is now estimated that there are 2 million cases annually with 1.5 million of 
the cutaneous form and 500,000 of the visceral form and with around 12 million 
people infected throughout the 88 countries currently affected [9]. More surprising is 
that only 32 of the 88 countries that are affected by the disease actually have to 
report leishmaniasis infection. The actual numbers could be dramatically different [7]. 
1.1.3 Pathology 
Leishmaniasis can present in 3 main forms each dependent on the area of the body 
infected (Fig 3). 
 
 
Figure 3- Leishmaniasis infections 
(2) Mucocutaneous (3) Cutaneous (1) Visceral 
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1. Visceral leishmaniasis (VL), [10] [11] infects the internal organs of the patient 
attacking the liver and spleen. If left untreated VL is fatal.  
2. Mucocutaneous leishmaniasis (MCL), [12] [13] infects the mucous tissue of the 
nose and mouth. MCL infections self-heal but result in massive tissue damage 
and permanent disfiguration. 
3. Cutaneous leishmaniasis (CL), [14] [15] infects the skin of the patient and results 
in self-healing ulcers that permanently disfigure the skin. 
 Worldwide visceral leishmaniasis makes up for about 25% of infected patients. Of 
these cases 90% are found in India, Sudan and Bangladesh [16]. Temperature could 
play a part in the localisation of the parasite species in the host. Some species of the 
parasite causing cutaneous leishmaniasis cannot grow at the core body temperature 
while species causing visceral leishmaniasis can [17]. The parasitic species causing the 
Leishmania infections can be put into three large species groups and three less 
diverse groups [18]. The parasites in these groups all have a similar physical 
appearance but with differing clinical manifestations. 
 3 Large Groups: 
1. L. braziliensis - cutaneous and mucocutaneous leishmaniasis in the Americas 
2. L. mexicana - cutaneous leishmaniasis in the Americas 
3. L. donovani – visceral leishmaniasis and 2 related members L. infantum in the 
Mediterranean and L. chagasi in the Americas. 
22 
 
The three small groups are L. major and L.tropica both causing cutaneous infections 
in Africa and the Middle East. L. aethiopica causes cutaneous infections in the North 
East of Africa.  
 
1.1.4 Parasite life cycle 
The parasite life cycle is a complex one surviving in the vector and the mammalian 
host and the many different environments this provides. The vector for the 
leishmania parasite is a certain species of sand-fly (Fig 4) from the genus 
Phlebotomus
 [19]. 
 
Figure 4 – Sand-Fly vector for Leishmania 
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Although there are around 500 different species of sand-fly (phlebotomine) only 
around 30 have been found to be vectors of the leishmania parasites[20]. 
 
 
 
Figure 5 – The infectious cycle of Leishmania [21] 
 
Starting with a bite of an infected sand-fly into a non-infected host, the parasite 
promastigote metacyclic form is transmitted to the host. The parasite enters from 
vector to host with the anti-clotting factors which are injected normally by the sand-
fly to ensure a steady blood flow. From here, the injected metacyclic parasites 
invade the host’s macrophages. In these macrophages the parasite differentiates 
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into the amastigote form and multiplies. The cells break down leaving the parasites 
free to infect other cells. This process repeats until treatment clears the infection or 
death. When another sand-fly, this time uninfected, takes a blood meal from the 
infected host it will ingest some of the parasites released from the macrophages. 
These enter the fly and attach to the mid-gut of the vector. From here they 
transform back to the procyclic form, multiply and travel to the mouth of the sand-
fly where they are ready to be excreted in the next blood meal. During its complex 
life cycle the trypanosomatidae exhibits 2 distinct morphological states[22]. 
Promastigotes replicate in the midgut of the sand-fly vector and then transform into 
their infective metacyclic form. They are ingested into the macrophages, where they 
differentiate and proliferate as amastigotes in the phagolysosome compartment. 
Good reviews have been published on the Leishmania-sand fly interaction [23], the 
transmission mechanisms of the metacyclic promastigote [24] and the metabolism of 
amastigotes inside human macrophages[25][26]. 
 
1.1.5 Treatment  
 The most common treatment for leishmaniasis is a chemotherapy approach using 
pentavalent antimonials administered parenterally. The main compounds used are 
meglumine antimoniate and sodium stibogluconate, but the actions of these drugs 
are not totally understood [27][28]. If the antimonials have no effect, alternative 
approaches are available using amphoterocin B, pentamidine and paromomycin. 
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These approaches are expensive, moderately effective, toxic and the parasite is 
starting to show resistance[29][30]. There is no vaccine for leishmaniasis but there are 
a number currently going through clinical trials [31][32][33][34]. There is still a great need 
for treatments for leishmaniasis. 
1.1.6 Diagnostics  
Diagnosis of an active leishmaniasis infection can be tricky. In the cases of cutaneous 
and mucocutaneous infections this is straight forward as they present with skin 
lesions. Treatment can be immediate and the confidence in diagnosis is high. In the 
case of visceral leishmaniasis this is very different. Visceral leishmaniasis attacks the 
internal organs and if not treated in a timely manner is fatal. To complicate things 
further the symptoms caused by the infection are very similar to other diseases such 
as malaria[35]. The longer the patient spends untreated the more at risk the 
community becomes as the patient will act as a reservoir for the disease. To make 
matters worse the medical staff want to be sure of the diagnosis before the start of 
treatment due to the toxic and expensive drugs they will have to administer for the 
treatment length of 3 weeks[35]. 
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1.1.6.1 Gold standard Test 
The gold standard test (the best test) uses peripheral blood or aspirates from 
marrow, spleen, lymph nodes. These are gathered by biopsies of the specific area. 
The cells are then placed on a slide, stained and viewed under a microscope (Fig 
6)[37]. 
 
Figure 6 – Bone marrow aspirate smear of visceral leishmaniasis 
 
These biopsy and microscope techniques are very effective but require sterilised 
conditions, high level of training, high tech equipment and after care. This would be  
no problem in the developed world, but as most visceral leishmaniasis cases are 
found in the developing world (India, Sudan and Bangladesh) this equipment and 
expertise are not available to the vast populations.  
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What is required is a robust simple field test kit that can be run anywhere and with 
results that can be trusted. 
 
1.1.6.2 Latex agglutinaion test - KAtex 
The test has been developed to provide accurate results for the infection of visceral 
leishmaniasis patients in the field. The general procedure for the test is below : 
1. Collect patient’s urine. 
2. Take 1ml on urine and boil  for 5 mins and allow to cool. 
3. Add 50ul of the boiled urine to the reaction zone on the test plate. 
4. Add 1 drop of the testing latex on to the sample of urine. 
5. Stir both liquids to form homogenous mixture. 
6. Tilt the plate with a rotating action – clockwise and anti-clockwise for 2 mins. 
7. After 2 mins, read the degree of agglutination obtained. 
The test works by using antibodies bound to the latex, these antibodies then bind to 
the antigen in the urine, with agglutinaion as a positive result. The results from the 
test can be read fairly quickly and can be done by eye, so no complicated machines 
are required. This test has drawbacks when it comes to the “field setting”. The 
boiling of the urine is possible in most settings but can cause problems in some. The 
tests themselves have to be kept at 4 oC and the kit itself is only for a minimum of 
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100 tests [38]. The sensitivity of the test needs to improve as in a study the KAtex test 
result was positive in 87% of a large sample, the largest evaluated to date, a 
sensitivity > 95% is ideal for a diagnostic test[39]. 
 
1.1.6.3 Lateral Flow test – rK39 RDT 
This dipstick style lateral flow test which can provide a result using a drop of blood 
collected from a patient and provide results in around 10 min. Fig 7 below provides 
an overview to how the test is run. 
 
Fig 7 – rK39 dipstick test [35] 
 
These tests are very simple to run and only require a fresh drop of blood collected 
from a whole blood sample and a few drops of the buffer solution to give a result. 
The testing reagent is thought to be antibodies that recognise other antibodies in 
the blood sample, these are already present on the strip so no addition of reagents is 
necessary. Through capillary action the sample passes along the strip where it comes 
into contact with the testing antibodies that bind any parasitic antibodies found in 
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the blood.  The test gives the results as either positive or negative. These tests are 
supplied individually wrapped, can be stored at room temperature and need no 
other equipment [38].  By looking for specific antibodies against the parasite; this is 
very good in patients with an active infection. The problem is that once the infection 
has been treated and cleared, the body continues to produce anti-bodies against the 
past infection. Due to the continual expression of antibodies after the infection has 
past (around 3-4 months after) this test will continue to read positive for an infection 
[40]. 
What is needed is a test-kit that brings the robustness of the rK39 RDT test, with 
detection of an active infection allowing treatment to stop when the infection stops. 
So the test would need to detect something that is parasite specific, and only 
present when the parasite is active in the patient. 
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1.1.7 Leishmania surface coat 
The surface coat of the Leishmania parasite is very complex and is very important in 
the survival and infectivity in both the insect vector and mammalian host. Many of 
the major cell-surface macromolecules found on the surface are anchored to the 
plasma membrane by glycosylphosphatidylinositol (GPI) anchors. Glycoconjugates 
expressed by the Leishmania parasite during the promastigote stage, are seen in Fig 
8 [41] [42] [43]. 
 
Fig 8 – Representation of the major cell-surface glycoconjugates of Leishmania [44] 
The lipophosphoglycan (LPG) is a complex glycolipid forming a dense layer on the cell 
surface. The dense layer is made up with around 6 x 106 copies per promastigote 
cell. The LPG structure is made up of a GPI anchor linked to a phosphoglycan 
backbone of a repeat unit made up of Galβ1-4Manα1-PO3H known as the 
phosphoglycan repeats (PG).  
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Figure 9 – Leishmania surface coat [45] 
 
Glycoproteins such as GP46 [46], promastigote surface protease GP63 [47] and 
secreted forms of proteophosphoglycans[48] and finally a family of heterogeneous 
class of structurally related densely packed low-molecular mass 
glycoinositophospholipids (GIPLs) can be found on the surface [41][42]. 
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1.1.8 The Structure of the Lipophosphoglycan (LPG) 
The LPG has 3 main parts to its structure; the first is a phosphoinositol lipid anchor 
which binds to the cell surface holding the entire structure in place. Bound to this is 
a phosphosaccharide core which is also bound to the second important structure, 
the repeat domain, which is made up of the repeat unit Galβ1-4Manα1-PO3H. The 
final part is an oligosaccharide cap to terminate the chain[42]. The anchor and 
phosphosaccharide core are much conserved in the Leishmania parasite. There are 
conserved areas in the repeat unit structure (the backbone) but it does contain some 
very species specific and life cycle specific variations. This can be clearly seen in Fig 
10. 
 
3
β-D-Galp-(1→4)-α-D-Manp-(1-PO3H-[-6)-β-D-Galp-(1→4)-α-D-Manp-(1-PO3H-]n
L. mexicana  amastigote-specific proteophosphoglycan [57],                                   Y = H
L. donovani  promastigote [49] [50],                       X = Y = H
L. mexicana  promastigote [51] [52],                       X = β-D-Glcp-1- (0.25),       Y = H
L. major  procyclic promastigote [53] [54] [55],     X = β-D-Galp-1- (0.52),
β-D-Galp-(1→3)-β-D-Galp-1- (0.25),  β-D-Arap-(1→2)-β-D-Galp-1- (0.09);  Y = H
L. major  metacyclic promastigote [53] [54] [55],   X = β-D-Galp-1- (0.31),
β-D-Galp-(1→3)-β-D-Galp-1- (0.06),  β-D-Arap-(1→2)-β-D-Galp-1- (0.45);  Y = H
L. aethiopica  promastigote [56],                      X = β-D-Galp-(1→3)-β-D-Galp-1- or
                                                                           β-D-Galp-1-;  Y = α-D-Manp-1- (0.35)
2
X Y
α-D-Manp-(1-PO3H-6)-β-D-Galp-(1→3)-β-D-Glcp-1-
H-[-6)-β-D-Galp-(1→4)-α-D-Manp-(1-PO3H-]2-6)-[β-D-Glcp-(1→3)]2-β-D-Galp-(1→4)-α-D-Manp-(1-PO3H-6)-[β-D-Glcp-(1→3)]2-
β-D-Glcp-(1→3)-β-D-Glcp-1-
Z  =  [α-D-Manp-(1→2)]5-α-D-Manp-(1-PO3H-6)-β-D-Glcp-(1→3)-β-D-Glcp-(1→3)-β-D-Glcp-1-
3
Z
=  X
α-D-Manp
α-D-Manp
2
2
1
1
(+/−)
(+/−)
 
Fig 10 - LPG differences by species  
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The different species of Leishmania alter their LPG structure by adding branched 
sugars at different points, but always conserving the repeat unit backbone. 
 
1.1.9 The role of the lipophosphoglycan 
The characteristics and role of the LPG have been discussed extensively in reviews 
[58][59] . The LPG is associated with many important steps in the Leishmania infectious 
life cycle of both the vector and host [41][42][43]. It has been seen in knock out studies 
(knocking out genes used in the biosynthesis of the LPG) that the LPG is needed for 
the survivability of the parasite [21][58][59]. This makes the area of LPG biosynthesis an 
area of great interest.  
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1.1.10 The biosynthesis of the lipophosphoglycan repeat unit. 
The Galβ1-4Manα1-PO3H repeat unit which makes the backbone of the LPG 
structure is made by sequential addition of mannosylphosphate and galactose[60] 
performed by a mannosylphosphate transferase (MPT) and a glactosyltransferase 
(GT) as seen in Fig 11. 
 
Figure 11 – Biosynthesis of LPG repeat domain 
The repeat unit structure is not specific to the LPG; it is a structural component in 
many other glycoconjugates such as secreted and membrane proteins including sAP 
and PPGs. Since the repeat unit is used in many structures unique to the parasite 
including the extra-cellular LPG and secreted PPG’s, it was thought that these repeat 
unit structures might be detectable. If it is  possible to detect these structures then it 
would give a valuable parasite specific biomarker.  
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1.1.11 Detection of phosphoglycan repeats 
In the lab of Marcel Hommel in the Liverpool School of Tropical Medicine a low 
molecular weight antigen (LMWA) was identified in the urine of visceral 
leishmaniasis patients[61]. The methods they employed included;  Capture ELISA, 
enzyme detection, trichloroacetic acid treatment, ethanol and acetone precipitation, 
Periodate treatment, Phenol-water extraction, Lipid extraction, Biotinylation, Affinity 
transfer blotting, Triton X-114 phase separation, Purification of GIPL’s and finally 
detection by Leishmania anti-glyconjugate monoclonal antibodies. Unfortunately the 
group were unable to determine the structure of this LMWA they found, all they 
could say was that it was carbohydrate in nature and had very good binding with 
monoclonal antibodies raised against the LPG[62][63]. This meant the structure found 
in the urine of the infected patient was some form of phosphoglycan repeat 
structure fragments from either the LPG or a PPG[63a]. 
This was further confirmed by Ferguson’s group in Dundee who were able to identify 
the phosphoglycan repeat structures by electrospray mass-spectrometry[64]. The 
methods used were able to confirm the structure of the LPG fragments and could 
even detect any branched sugars from the various parasites. This method will enable 
us to type the LPG’s and PG’s in the biological samples such as urine.  
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1.1.12 A Possible New Test-kit for Leishmaniasis.  
With the results talked about in the previous section it is now possible to think about 
a new diagnostic test-kit for leishmaniasis[38][39][40]. The main problem with the rK39 
dipstick test was that it could not detect when an infection had cleared because it 
detected the antibodies against the parasite. The new test looks for the antigen from 
parasite, this means when the parasite is gone (the patient is uninfected) there will 
be a negative result meaning treatment can halt. The urine of the patient will be 
tested, thus avoiding having to take blood from patients who live in areas with very 
high HIV+ infection rates. 
By maintaining the idea of a lateral flow test (dipstick)(Fig 12 and 13) we can design a 
test using the phosphoglycans from the parasite and the antibodies to recognise 
them. 
 
Figure 12 & 13 – lateral flow test ideas. 
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In this test, the urine (infected or not) is placed at the start of the strip and is 
immediately mixed with the anti-phosphoglycan antibodies bound to a marker. For 
an infected sample it is expected any phosphoglycans (PGs) in the urine will be 
picked up by the antibodies. Through capillary action the urine/antibody mixture is 
washed along the plate where it comes across synthetic PGs. For an infected sample 
there should be no binding with the synthetic PGs due to all antibodies being 
blocked by PGs found in the urine. For an uninfected sample there should be binding 
with the synthetic PGs. The capillary action continues to move the sample to end 
point where the test is complete. For an uninfected patient there would be 2 bands, 
one to show binding with the synthetic PGs and another to show excess antibodies 
at the end (Fig 12). For an infected patient there would be one band, at the end, as 
there should be no binding with the synthetic PGs due to all antibodies being 
blocked by PGs found in the urine. 
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For this test to work synthetic phosphoglycans are needed, thus providing the 
positive and negative comparison. They must be designed so they are recognised as 
the repeat unit structure and they must contain a region that can be bound to a solid 
surface for testing. A selection of repeat unit lengths (1 - 3)should be synthesised 
(Fig 14). Once synthesised, the compounds will undergo ELISA experiments to 
measure the binding of the monoclonal antibodies to establish how many repeat 
units are needed. Once this is complete the next steps will involve comparing the 
binding to antibodies and urine samples of infected patients.  The synthesis of these 
compounds makes up the core topic of this thesis. 
 
 
Figure 14 – Synthetic phosphoglycan repeats linked to biotin moiet 
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1.2 Chemical Introduction 
1.2.1 Chemical synthesis of Leishmania LPG repeats 
The development of synthetic approaches to phosphoglycans in general and 
Leishmania LPG in particular is not an easy task because of the hydrolytic lability of 
the phosphodiester bridges, which link the repeating units through the anomeric OH 
of D-mannose and the 6-OH of D-galactose. Wide-ranging reviews of Leishmania 
phosphoglycans have been published. [65][66][67] These reviews cover a variety of 
approaches, stepwise, blockwise, polymer-supported and polycondensation, for the 
chemical synthesis of phosphoglycans. 
 
 
 
Fig 15 – Structure of the LPG of L. donovani and L. major 
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As described before the LPG domain contains the oligosaccharide cap, the repeat 
domain and the GPI anchor. The size of the repeat domain depends on the parasites 
stage of development. Many groups have been working on the synthesis of the LPG 
concentrating on different areas. The Vishwakarma [68], Fraser-Reid [69] and 
Seeberger [70][71] groups synthesised the LPG cap domain. Synthesis of the 
Leishmania LPG core has been performed jointly by two groups: Oscarson and co-
workers [72] and Konradsson and co-workers [73][74]. The LPG repeat domain has been 
worked on by two main groups, Nikolaev’s group from University of Dundee and 
Vishwakarma’s group from New Delhi. Both have attempted synthesis of the repeat 
units using different synthetic strategies. Since the important synthetic aim of the 
project is to produce repeat unit structures the different approaches will be 
discussed. 
 
1.2.2 Nikolaev and co-workers 
The first successful syntheses of the Leishmania phosphoglycans were achieved by 
the Dundee University based group [75] [76] by exploiting H-phosphonate chemistry. 
Several successful syntheses of L. donovani phosphoglycans containing 2 and 3 
repeat units and with the cap unit attached were synthesised (Scheme 1) using the 
stepwise approach to chain elongation. The glycosyl H-phosphonate route was 
proven to be the method of choice for the efficient and reliable assembly of various 
phosphodiester linkages[77]. 
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Scheme 1 –Stepwise synthesis of phosphoglycans of L. donovani. [78] 
 
Protected tetrasaccharide phosphate 8 was synthesised by the coupling of the 
disaccharide H-phosphonate 4 and the disaccharide 6 with one free hydroxyl group, 
followed by the removing of the DMT protecting group. Addition of another H-
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phosphonate 4 and subsequent oxidation yielded the hexasaccharide diphosphate 7 
after de-O-tritylation. Further chain extension using the disaccharide H-phosphonate 
5 and compounds 7 followed by global deprotection gave the octasaccharide 
phosphoglycan 9. Protected fragments 7 and 8 also underwent global deprotection 
giving compounds 10 and 11, respectively. 
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Scheme 2 – Stepwise strategy to L.mexicana LPG 
Using the stepwise addition of H-phosphonate units 4 and 12  the branched 
phosphoglycan of L. mexicana 13 was synthesised (Scheme 2)[79]. In addition, several 
LPG fragments from L. major were also prepared. [80][81][82][83][84] 
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A blockwise approach was also developed by Nikolaev et al. [85] this involves the 
condensation of two phosphodiester blocks: the H-phosphonate derivative 15 and 
6'-hydroxyl acceptor 14 for the synthesis of the hexaglycosyl triphosphate 16, which 
is a terminal fragment of the phosphoglycan portion of L. donovani LPG (Scheme 3). 
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Scheme 3 –Blockwise strategy to L.donvani phosphoglycan 
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1.2.3 Vishwakarma and co-workers 
Vishwakarma and co-workers also described an iterative synthesis of the L. donovani  
phosphoglycan 19 (Scheme 4). [86][87]as well as the branched phosphoglycan 20 of 
L.major (Scheme 5)[88] using traditional solution phase 
chemistry.
 
Scheme 4 – The preparation of L. donovani phosphoglycans 
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Scheme 5 - The preparation of the branched phosphoglycan of L. major. 
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1.2.4 Anchor and Spacer Selection 
 The anchor part of the synthetic phosphoglycans 1-3 (Fig 14) must be stable during 
the chemical synthesis and when needed bind to a solid surface. The anchor that 
was chosen was biotin (Fig 16); vitamin H or Coenzyme R has been used for many 
biological applications. By biotinylating unknown proteins or compounds in solution 
they can be anchored and identified. The anchoring occurs with the use of avidin 
proteins which bind biotin with a very high affinity (Kd ~10
−15 mol/L). This provides 
the biochemists with the ability to capture unique compounds from solution.  
HN NH
S
HH
H
H (CH2)4COOH
H
O
 
Figure 16 – Biotin 
 
Biotin will be incorporated into the synthetic phosphoglycans with a spacer molecule 
which will be 6-aminohexanol. The spacer is used just to separate the phosphoglycan 
repeats and the biotin. There has not been a great deal of work from a synthetic 
carbohydrate chemistry perspective using biotin but a paper modifying biotin [89] was 
published from the laboratory of Nikolaev and will form the basis of chemistry 
involving biotin. 
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2. RESULTS AND 
DISCUSSION 
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2.1. Aims of the project 
 A biomarker for the Leishmania parasite has been identified in the lab of Mike Ferguson 
in Dundee. It was found that this biomarker is a ...-6-β-D-Galp-(1-4)-α-D-Manp-(1-OPO2H-
... (Fig 17) repeat unit of the repeat domain of the lipophosphoglycan (LPG), the most 
abundant macromolecule on the surface of promastigote forms of all Leishmania species. 
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...-6-β-D-Galp-(1→4)-α-D-Manp-(1-OPO2H-...  
Fig 17- Repeat domain and the repeat unit of Leishmania LPG 
 
This repeat unit was found to be detectable in the urine of an infected patient, and since 
this phosphoglycan structure is parasite specific it gives a very good basis for a diagnostic 
test. Furthermore, since this phosphoglycan is parasite specific once the infection has 
been treated there will be no biomarker present in the patient. In further work 
monoclonal antibodies were identified that recognise this structure and could be used as 
part of the test kit. So, the idea of a test kit was put together (Fig 18) where the urine of 
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an infected patient would be tested with the antibodies to give a result either positive for 
an active infection (Fig 18) or negative for no infection (Fig 19). 
 
 
Fig 18 – Positive test 
 
Fig 19 – Negative test 
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With this style of dipstick test a positive control is needed, so synthetic compounds of the 
repeat unit must be synthesised. The repeats must be recognised by the antibody and 
provide detectable binding to provide a result. These repeats must also be able to bind 
with a surface on which the testing can occur. 
Three target compounds 1-3 (Fig 20) were decided upon of different repeat unit lengths, 
all attach to a biotin moiety that can be used to anchor the compounds to an avidin-
coated surface. 
O
OH
HO
O
O
OH
OH
O HO
O
OH
HO
HO OH
O
O
OH
OH
O
HO
P
O- +HNEt3
O
O
OH
HO
HO
O
O
OH
O
HO
HO
OH
O
OH
HO
OH
O
O
OH
OH
O HO
P
O- +HNEt3
O
HO
NHHN
S
H H
H
H
H
O
O(CH2)6NHC(O)(CH2)4
O
OH
HO
O
O
OH
OH
O HO
O
OH
HO
HO
OH
O
OH
O
HO
HO
OH
O
P
O- +HNEt3
O
O
O
P
O- +HNEt3
O
O
1
2
3
P
O- +HNEt3
O
NHHN
S
H H
H
H
H
O
O(CH2)6NHC(O)(CH2)4
P
O- +HNEt3
O
NHHN
S
H H
H
H
H
O
O(CH2)6NHC(O)(CH2)4
 
Fig 20 – Original target compounds: biotinylated LPG fragments 1-3 
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After the synthesis of the compounds they will undergo biological testing in an ELISA 
assay to measure the binding with the antibody to establish which compound length is 
most suitable. 
 
2.2. General synthetic design 
 The chemical preparation of compounds 1-3 was attempted and appeared to be 
unsuccessful (see Section 2.3.7), although an alternative strategy was developed later 
(see Section 2.5), which was successful for the preparation of different structures 
containing one, two and three repeat units connected to a biotin moiety. This was 
completed using the synthetic schemes which contained a few general steps: 
1) Preparation of selectively protected monosaccharide and disaccharide derivatives. 
2) Preparation of protected H-phosphonate derivatives. 
3) Preparation of protected phosphoglycan structures using the glycosyl H-
phosphonate condensation method (including biotin addition). 
4) Total deprotection through de-O-benzoylation. 
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2.3 Synthesis of 6-N-Biotinylaminohexyl 2,3,6-tri-O-benzoyl-4-O-[2,3,4-
tri-O-benzoyl-6-O-(p,p’-dimethoxytrityl)-β-D-galactopyranosyl]-α-D-
mannopyranosyl phosphate, triethylammonium salt 42 
A retrosynthetic scheme that enables the synthesis of the target compounds has been 
identified (Scheme 8). The building blocks required for the compounds 1-3 are a modified 
(with 6-aminohexanol linker) biotin derivative 27 and the repeat unit β-D-
galactopyranosyl-(1→4)-α-D-mannopyranosyl H-phosphonate derivative 34. 
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Scheme 8 - Retrosynthetic strategy to the disaccharide phosphate 42, which is a protected derivative of the 
target compound 1 
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For the additional target compounds 2 and 3 extra repeat units will be added through the 
chain elongation using the protected disaccharide H-phosphonate derivative 34. This was 
to be done after the incorporation of the biotin derivative to the first repeat. 
 
2.3.1 Synthesis of 1,2,3,6-Tetra-O-benzoyl-α-D-mannopyranose 21 
The glycosyl acceptor 21 (Scheme 9) for the disaccharide synthesis is a α-D-
mannopyranose derivative protected at positions 1,2,3 & 6 with a benzoyl protecting 
group leaving the hydroxyl at position four free[91]. This can be done by selective 
benzoylation using a dropwise addition of a strict 4 eq. of benzoyl chloride to a solution of 
D-mannose in pyridine at -40 oC. 
 
OHO
HO
OH
OH
OH
OHO
BzO
OBz
OBz
OBz
BzCl (4 eq)
Py
21  
Scheme 9 – Preparation of the glycosyl acceptor 21 
 
Use of a strict 4 eq. of the reagent means the benzoyl chloride will react with the most 
reactive HO-groups first leaving the least reactive unprotected. In the case of D-mannose 
4-OH is the least reactive group giving the required selectivity. Derivative 21 was 
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recrystallised from ethyl acetate and n-hexane giving crystals with a melting point of 184-
185 o C. 
 
2.3.2 Synthesis of 2,3,4-Tri-O-benzoyl-6-O-tert-butyldimethylsilyl-α-D-
galactopyranosyl trichloroacetimidate 24 
The D-galactopyranosyl trichloroacetimidate 24 (Scheme 10) was synthesised starting 
from D-galactose. 
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Scheme 10 – Preparation of the glycosyl donor 24 
D-Galactose was firstly reacted with tert-butyldimethylsilyl chloride in pyridine for 2 
hours. This provided a silyl protecting group at position 6, which would become important 
in further steps. Once the silyl protection was in place, benzoyl chloride (10 eq) was 
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added to protect the rest of the free hydroxyls of D-galactose. After a work-up and 
purification on silica gel this gave a fully protected galactose derivative 22 in a good yield 
of 82 %. The next step required the formation of the hemiacetal by removing the 
benzoate from the anomeric position. This was done using two methods, the first used 
dimethylamine (2M) in THF and this method took around 12 hours and gave a yield of 
59% [90][91]. The second method took considerably longer at 30 hours but the yield was 
higher at 75%; this method used ethylenediamine and acetic acid in THF[92]. Both methods 
were used during the repeated syntheses of the hemiacetal 23. Formation of the glycosyl 
donor 24 from the hemiacetal was done using trichloroacetonitrile and a catalytic amount 
of cesium carbonate in DCM [93][94]. The reaction took around 1 hour to complete, with the 
yield of 64 %. The formation of the glycosyl trichloroacetimidate 24 was verified with by 
1H and 13C NMR. From the 1H NMR the signal for the NH of the trichloroacetimidate at 
8.69 ppm, can be clearly seen. 
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2.3.3 Synthesis of 1,2,3,6-Tetra-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-
butyldimethylsilyl-β-D-galactopyranosyl)-α-D-mannopyranose 30 
With the synthesis of the glycosyl donor 24 and the glycosyl acceptor 21 the derivative to 
form is the protected disaccharide 30 (Scheme 11). 
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Scheme 11 – Preparation of the disaccharide 30 
 
The glycosylation of the 4-OH D-mannose acceptor 21 with the trichloroacetimidate 
galactose donor 24 was catalysed by Trimethylsilyl trifluoromethanesulfonate (TMSOTf), 
with molecular sieves 4Å to ensure anhydrous conditions[95]. The reaction proceeded 
smoothly with the major product being the β−linked disaccharide 1,2,3,6-tetra-O-
benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-butyldimethylsilyl-β-D-galactopyranosyl)-α-D-
mannopyranose 30 formed in a 72 % yield.  
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2.3.4. Synthesis of 2,3,6-Tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-
dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranose 33 
2.3.4.1 Method A 
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Scheme 12 – Preparation of the disaccharide 33 
 
From derivative 30 removal of the silyl protection group was carried out using a mixture 
of 40 % aq. HF and acetonitrile (1:3) at 0 oC[96]. This removed the silyl group at position 6 
and provided the disaccharide 31 (Scheme 12) in a 95 % yield. This was further proved by 
the complete disappearance of the tert-butyldimethylsilyl signals in the 1H and 13C NMR 
of 31. Compound 31 was then re-protected at position 6 of the D-galactose residue, this 
time with a p,p’-dimethoxytrityl protecting group. The reason for the replacement of the 
protecting group at this stage and not at the beginning of the synthesis of the 
59 
 
disaccharide 30 is due the very acid sensitive nature of the p,p’-dimethoxytrityl protection 
(which proved to be highly beneficial during further phosphosaccharide chain elongation). 
O
Si
O
O O
TBS protection DMT protection  
Scheme 12a – TBS and DMT protecting groups 
 
 If the p,p’-dimethoxytrityl group was present from the beginning of the synthesis during 
the previous step of glycosylation (see Section 2.3.3) it would have been cleaved. This 
would have resulted in two free hydroxyl groups during the glycosylation reaction 
resulting in many side products. By changing the TBS protecting group to the DMT 
(Scheme 12a) this gives fast effect removal, 2 min for p,p’-dimethoxytrityl compared with 
3 h for silyl. In addition, the p,p’-dimethoxytrityl derivatives can be easily identified by the 
bright orange colour they give when detected on TLC plates with a mixture of sulphuric 
acid-water-ethanol (15:85:5). Tritylation of compound 31 was carried out with p,p’-
dimethoxytriphenylmethyl chloride in pyridine. This took around 15 h to complete giving 
the derivative 32 in an 82% yield. The formation of the hemiacetal 33 was carried out 
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using the dimethylamine method [90][91] yielding 70% in 20 h and the ethylenediamine 
method [92] was complete in 40 h giving a yield of 75%. Dimethylamine was used as the 
method of choice in this step due to the lower reaction time. With the hemiacetal 
disaccharide 33 prepared in a good yield over the 4 steps (starting from monosaccharide 
compounds 21 and 24), the building block for the H-phosphonate disaccharide repeat unit 
derivative, was now available 
 
2.3.4.2 Method B 
Another method for the formation of this DMT protected disaccharide 32 was designed. 
This method (Scheme 13) reduces the number of steps and purifications needed to 
synthesise this compound.[93] 
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Scheme 13 – Alternative synthesis of the disaccharide 32 
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The pentaacetate of β-D-galactose underwent anomeric deprotection with 
dimethylamine in THF.[90][91] After 1 h it could be seen (monitoring by TLC) the reaction 
was complete, and the crude hemiacetal derivative was taken straight into the next step. 
The formation of the trichloroacetimidate 29 was carried out in DCM with 
trichloroacetonitrile and a catalytic amount of cesium carbonate[97]. After 2 h the reaction 
was worked up and the product was purified. This gave the trichloroacetimidate 29 in a 
yield of 80% for the two steps. The glycosylation reaction between derivative 29 and the 
tetrabenzoate 21 was carried out with TMSOTf as the catalyst, and run for 30 min at -40 
oC [95][97]. Purification of the reaction products resulted in the disaccharide 39 in a yield of 
88 %. The disaccharide 39 then underwent a deprotection step to remove all the acetate 
groups from the D-galactose residue, which was achieved by using HCl in MeOH. This 
method is highly selective to cleave O-acetyl protecting groups in the presence of benzoic 
esters [98]. Once the de-O-acetylation was complete the reaction was quenched and 
worked-up. The next step was to dissolve the product in pyridine and add the p,p’-
dimethoxytriphenylmethyl chloride; this was left for 20 h after which benzoyl chloride 
was added and the reaction mixture was left for a further 15 h [97]. The reaction was then 
stopped and worked-up; after the purification the disaccharide 32 was isolated in a 91 % 
yield for the 3 steps.  
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2.3.5 Synthesis of 2,3,6-Tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-
dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranosyl 
hydrogenphosphonate, triethylammonium salt 34 
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Scheme 14 – Preparation of the disaccharide H-phosphonate with PCl3, imidazole and Et3N 
 
The synthesis of the H-phosphonate derivative 34 was achieved via the disaccharide 
hemiacetal 33 (Scheme 14). Phosphitylation of the hemiacetal was carried out using tri-
imidazolylphosphine, which was prepared in situ from PCl3, imidazole and Et3N, followed 
by hydrolysis with aq. TEAB buffer solution (pH 7.8)[99][100]. This provided the glycosyl H-
phosphonate derivative 34-α,β in a very good 95 % yield, but as an anomeric mixture at 
the D-mannose residue with α/β ratio of 12:1. To proceed on in the synthetic strategy a 
ratio of >20:1 would be preferred to ensure the correct anomeric configuration. To 
improve the α/β ratio, the derivative 34-α,β was reacted with silver triflate and methanol 
for 40 min at room temperature[101]. This allowed degradation (solvolysis) of the β-H-
phosphonate back to the original hemiacetal 33 (Scheme 15). The glycosyl β-H-
phosphonate (with equatorial H-phosphonic moiety at C1) is known to be less stable than 
the corresponding α-anomer (with axial H-phosphonic moiety at C1), which is favoured 
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by the anomeric effect [102]. It was seen by 31P NMR that there was no β-anomer present 
and the pure α-anomer 34 was isolated in a 50% yield. The hemiacetal 33 was recovered 
and used again to prepare the disaccharide H-phosphonate. 
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Scheme 15 – ‘Correction of the configuration’ with silver triflate and MeOH 
 
Due to the anomeric mixture formation with PCl3, imidazole and Et3N and a moderate 
yield in the 2-step synthesis (formation of the H-phosphonate and ‘correction of the 
configuration’) another method was tried for the formation of the H-phosphonate 34. 
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Scheme 16 – Preparation of the disaccharide H-phosphonate with salicyl chlorophosphite 
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This method [103][104] used salicyl chlorophosphite and Et3N in acetonitrile reacting with 
derivative 33 (Scheme 16) for 1 h at room temperature, followed by hydrolysis with aq. 
TEAB buffer solution (pH 7.8). After purification the H-phosphonate 34 was isolated in a 
98% yield and by 31P and 1H NMR it could be seen that there was only the α-anomer. As 
this method gave pure α-H-phosphonate, there was no need to correct the configuration. 
This 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-dimethoxytrityl)-β-D-
galactopyranosyl]-α-D-mannopyranosyl hydrogenphosphonate 34  is the first building 
block and also the repeat unit in the synthetic strategy. The next building block to 
synthesise is the biotin component.  
 
 
 
65 
 
2.3.6 Synthesis of 6-N-Biotinylaminohexanol 27 
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Scheme 17 – Preparation of 6-N-biotinylaminohexanol 27 
 
Synthesis of the biotin derivative 27 (Scheme 17) was achieved by converting D-biotin to 
the p-nitrophenyl ester 26 and then addition of the spacer molecule 6-aminohexanol[106]. 
Compound 27 is the building block that will react with the disaccharide H-phosphonate to 
form the first of the target molecules. A mixture of D-biotin, p-nitrophenyl 
trifluoroacetate and p-nitrophenol in pyridine was heated to 55 oC for 2 h [105][106]. The D-
biotin p-nitrophenyl ester 26 was recrystallised from ethanol, giving a yield of 72 % of the 
crystals. The ester 26 was added to 6-aminohexanol in DMSO, and the mixture was left 
for 20 h [105] at room temperature. The derivative 27 was precipitated by the addition of 
acetone and diethyl ether giving 27 in a good 80 % yield. This gave our final building block 
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in this synthetic strategy leaving the next step the condensation between the protected 
disaccharide H-phosphonate 34 and the 6-N-biotinylaminohexanol 27. 
 
2.3.7 Synthesis of 6-N-Biotinylaminohexyl 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-
O-benzoyl-6-O-(p,p’-dimethoxytrityl)-β-D-galactopyranosyl]-α-D-
mannopyranosyl phosphate, triethylammonium salt 42 (protected form of 
the target compound 1) 
Before using the valuable disaccharide H-phosphonate 34 for the condensation with the 
biotin derivative 27, a trial experiment using 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl 
H-phosphonate 40 (Scheme 19) was performed. Compound 40 (Scheme 18), in turn, was 
synthesised from the O-benzoylated D-glucose hemiacetal 53, which was kindly donated 
by Dr Amina Fersia. 
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Scheme 18 – Preparation of the protected glucosyl H-phosphonate 40 
 
This was converted to the H-phosphonate derivative 40 [107][108] by reacting it with tri-
imidazolylphosphine formed in situ from PCl3 and imidazole in the presence of 
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triethylamine, followed by hydrolysis with aq. TEAB buffer solution (pH 7.8). This gave the 
monosaccharide H-phosphonate in a good 78 % yield. The next step was to condense this 
compound with the biotinyl derivative 27 (Scheme 19). 
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Scheme 19 – Preparation of 6-N-biotinylaminohexyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl phosphate 
41 
 
The compounds 27 and 40 were combined together using pivaloyl chloride as the 
condensing agent.  After 90 min at room temperature, I2 in a pyridine-water (95:5) 
solution was added to oxidise the intermediate H-phosphonic diester to the phosphate. 
After workup and purification on silica gel, the phosphodiester compound 41 was isolated 
in a 77 % yield and the structure was proved by 1H, 13C and 31P NMR data. This trial 
experiment was a good indicator that the condensation of the larger disaccharide unit 
should progress well and the conditions are well suited.  
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The condensation of the protected disaccharide H-phosphonate 34 and the modified 
biotin 27 (Scheme 20) was carried out in the same conditions as the model synthesis 
(Scheme 19) had been run. It was noticed after the oxidiation step that the biotin 
containing sugar derivative 42 was very polar on TLC and running just slightly above the 
unreacted biotin compound 27. This made the purification of the biotin sugar phosphate 
42 a lot more complicated to get a pure compound. On TLC it was also seen there was 
much cleavage of the H-phosphonate group in compound 34, which resulted in the 
disaccharide hemiacetal 33 as the major product. After workup and purification on silica 
gel a small amount of target compound 42 was recovered (8 %). This was just enough to 
run 1H and 31P NMR spectra to prove the structure of the product. 
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Scheme 20 – Preparation of 6-N-biotinylaminohexyl 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-
dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranosyl phosphate 
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Due to the very low yield of the compound and the difficulty in purifying biotinylated 
protected carbohydrate phosphates it was decided to abandon the method of biotin 
integration through a phosphate group at the beginning of the chemical chain elongation. 
Instead it was decided to look for a method introducing biotin later in the synthetic 
scheme thus avoiding the polarity issues that led to purification problems. 
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2.4 Attempted synthesis of biotinylated phosphosaccharide 
compounds using a monosaccharide bridge to biotin 
A retrosynthetic scheme that incorporated the biotin moiety later in the synthetic 
scheme, while reducing the polarity of the overall protected molecule, was identified 
(Scheme 21). 
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Scheme 21 – Retrosynthetic approach using the monosaccharide bridge 
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The synthetic strategy enabled integration of the biotin moiety as a final step, allowing a 
stepwise or blockwise building approach to be used for chain elongation by simple 
removal of the p,p’-dimethoxytrityl protecting group. The D-galactose linker derivative 43 
can be coupled with the repeat unit H-phosphonate 34 by a condensation at the position 
6. Once the corresponding trisaccharide monophosphate is formed, removal of the Fmoc 
protection from amino group in the linker and coupling with the biotin p-nitrophenyl 
ester 26 should be possible. The first reaction to carry out was to test the coupling 
between the disaccharide H-phosphonate 34 and the Gal-linker-Fmoc derivative 43. 
 
 
2.4.1 Attempted condensation of 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-O-
benzoyl-6-O-(p,p’-dimethoxytrityl)-β-D-galactopyranosyl]-α-D-
mannopyranosyl H-phosphonate 34 and Gal-linker-Fmoc derivative 43 
The reaction was to form an inter-saccharide phosphate compound, which had been 
reported many times [67], but had never been attempted in the presence of the N-Fmoc 
protecting group. Compound 43 was synthesised and kindly donated by Dr Dimity 
Yashunsky for use in this experiment. Compounds 34 and 43 were combined (Scheme 22) 
and the reaction was run under standard condensation and oxidation conditions: pivaloyl 
chloride as the condensing agent and iodine in pyridine-water (95:5) for oxidation. 
72 
 
O
OHBzO
BzO
BzO
O(CH2)6NHFmoc
43
+
O
BzO
BzO
BzO ODMTr
O
O
OBz
OBz
O
BzO
P
H
O- +NHEt3
O
34
O
BzO
BzO
BzO ODMTr
O
O
OBz
OBz
O
BzO
P
O- +NHEt3
O
O
O
BzO
BzO
BzO
O(CH2)6NHFmoc
1. Pivaloyl chloride, Py
2. I2, Py/H2O (95:5)
 
Scheme 22 – Attempted coupling of the disaccharide H-phosphonate and Gal-linker-Fmoc derivative 
 
It could be seen on TLC plates that there was no reaction between the H-phosphate and 
the free hydroxyl of the galactose derivative. There have been many reactions, which 
have showed forming a inter-sugar phosphate link being successful [67], in this case it is 
unknown what stopped the reaction. One idea is that the N-Fmoc protection interfered 
with the condensation somehow, but due to the lack of previous experiments of this type 
containing this protecting group it remains just an idea. Due to this critical step not 
working, it was decided to abandon this synthetic strategy, and design another that 
would allow us to introduce the biotin moiety at the final step of the chemical chain 
elongation. 
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2.5 Synthesis of the target compounds 50, 51 and 52 with biotin moiety 
at the non-reducing end of the chain 
 
A novel approach was needed to circumvent the issues biotin was causing during the 
synthesis. It was accomplished by (i) changing the way the biotin moiety was introduced, 
from the reducing end (Scheme 8) to the non-reducing end of the chain and (ii) using the 
H-phosphonate biotin derivative 28 (Scheme 23). 
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Scheme 23 – Retrosynthetic approach introducing biotin to the non-reducing end of the chain 
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This would allow stepwise chain elongation with the disaccharide H-phosphonate 36 (as 
well as the disaccharide H-phosphonate 34) to form the larger phosphosaccharide units 
and biotin integration at the final step before the total deprotection. It was shown in 
Vishwakarma et al. [86][87] that the silyl protecting group at D-galactose position 6 of Gal-
Man-phosphate protected derivatives could be easily removed in presence of the 
phosphate group. So, it was decided to keep the silyl in place in compound 30 (Scheme 
12) rather than remove it and replace with a DMT protection as in former schemes. The 
disaccharide 30 was then converted to the disaccharide H-phosphonate 36 (see below). 
By adding biotin at the non-reducing end we require a permanent blocking group at the 
anomeric position of the terminal D-mannose unit, which could be a methyl glycoside. 
Thus, a methyl bioside derivative 38 should be prepared and used as the starting 
monohydroxyl disaccharide derivative for elongation of the phosphoglycan chain. By 
changing to this synthetic strategy this modifies our target molecules (Scheme 24), which 
now seem to be compounds 50, 51 and 52 containing one, two and three repeats, 
respectively, and all containing the biotin moiety linked via a 6-aminohexyl linker to a 
phosphate at the non-reducing end of the chain. 
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Scheme 24 – Modified target compounds 50, 51 and 52 containing biotin moiety at the non-reducing end of 
the chain 
 
2.5.1 Synthesis of methyl 2,3,6-tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl)-α-D-mannopyranoside 38 
Formation of the methyl bioside derivative 38 (Scheme 25) was performed using the 
glycosyl donor 24 from the previous glycosylation to form the repeat unit derivatives. This 
was coupled with the methyl mannoside derivative 25 [110][111] to provide the protected 
disaccharide 37. The next step was to remove the silyl protecting group at D-galactose 
position 6 to provide the hydroxyl for further phosphorylation. 
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Scheme 25 – Preparation of methyl glycoside derivatives 25, 37 and 38 
 
Methyl α-D-mannopyranoside was reacted with a strict 3 eq. of benzoyl chloride in 
pyridine at -40 oC. After 21 h the reaction was quenched, worked-up and purified to give 
the tribenzoate 25 in a good 71% yield. The glycosyl acceptor 25 was combined with the 
glycosyl donor 24 and TMSOTf to catalyse the glycosylation. It was found by doing repeat 
experiments the optimum temperature for this reaction was -40 oC. After purification 
disaccharide 37 was isolated in a 68 % yield. Treatment with aq. HF in acetonitrile for 1 h 
was enough to remove the silyl protection at the 6 position of the D-galactose in a 
quantitative yield. This gave the required monohydroxyl disaccharide compound 38 for 
further condensation with an H-phosphonate derivative. 
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2.5.2 Synthesis of 6-N-Biotinylaminohexyl hydrogenphosphonate 28 
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Scheme 26 – Preparation of the biotin H-phosphonate derivative 28 
 
Formation of the biotinylaminohexyl H-phosphonate 28 (Scheme 26) was achieved by 
reacting biotin-linker derivative 27 with salicyl chlorophosphite in DMF [106]. After 10 min 
the reaction was quenched with 1M TEAB buffer solution and diethyl ether was added to 
the reaction mixture, and it was then left in the fridge for 16 h.  This allowed the biotin 
derivative to precipitate out of solution giving compound 28 as an acid (H+-form) in a 90 % 
yield. 
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2.5.3 Synthesis of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-(6-N-biotinylaminohexyl 
phosphate), triethylammonium salt 44    
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2. I2, Py/H2O (95:5)
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Scheme 27 – Formation of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-
mannopyranoside 6-(6-N-biotinylaminohexyl phosphate) 44 
 
Before the start of the condensation reaction both compounds 38 and 28 (Scheme 27) 
were combined and dried by evaporation of pyridine therefrom to ensure strictly 
anhydrous conditions. The reaction was started by dissolving the mixture in pyridine, and 
triethylamine was added to convert the H-phosphonate 28 to the corresponding 
triethylammonium salt. Pivaloyl chloride was added to the mixture as the condensing 
agent, and after 60 min it was seen by TLC that compound 38 had been consumed. 
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Therefore the reaction product, the corresponding H-phosphonic diester, was oxidised by 
the addition of iodine in pyridine-water. After work-up and purification on silica gel, the 
protected biotin linked disaccharide phosphate 44 was isolated in an 84 % yield. The 
compound’s structure was proven by analysis of the 1H, 13C and 31P NMR (see Fig 21) and 
high resolution mass spectrometry data. This gave the protected form of the first of the 
target compounds, the one repeat unit linked to biotin in the O-benzoylated form. 
Deprotection of the compound was done once the other protected target compounds 
had been synthesised. With the successful synthesis of the first protected target 
compound, the next step was to form the two repeat unit compound. 
 
Fig 21:  31P NMR spectrum of 44 
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2.5.4 Synthesis of 2,3,6-Tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-
butyldimethylsilyl-β-D-galactopyranosyl)-α-D-mannopyranosyl 
hydrogenphosphonate, triethylammonium salt 36 
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Scheme 28 – Preparation of TBS protected disaccharide H-phosphonate 36 
 
Derivative 30 (for preparation, see scheme 12) was converted to the hemiacetal 35 by the 
reaction with ethylenediamine and acetic acid in THF (Scheme 28). After the work-up and 
purification this gave the product in an 87% yield. Hemiacetal 35 was then used for the 
formation of H-phosphonate derivative 36 by reacting it with salicyl chlorophosphite in 
acetonitrile. When it was quenched with TEAB buffer solution, worked-up and purified, 
this gave the desired product 36 in a 98 % yield. This H-phosphonate compound was used 
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as the preferred repeat unit derivative for the next step of the synthesis due to lower 
number of steps in the synthesis compared with its DMT containing counterpart. 
2.5.5 Synthesis of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-[2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl 
phosphate] triethylammonium salt 46 
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Scheme 29 – Formation and deprotection of the tetrasaccharide monophosphate 45 
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The condensation of compounds 36 and 38 (Scheme 29) was carried out under standard 
conditions[112], co-evaporations with pyridine to ensure dryness of the compounds, the 
use of pivaloyl chloride as the condensing agent and iodine in pyridine-water (95:5) for 
the oxidation. After purification on silica gel this gave the protected tetrasaccharide 
phosphate 45 in a very good 82 % yield. To remove the silyl protecting group from the 
derivative 45, treatment with a mixture of 40 % aq. HF and acetonitrile (1:3) at 0 oC was 
carried out for 2 h. This removed the silyl group while not harming the phosphate linkage, 
giving the tetrasaccharide phosphate 46 in a 90 % yield.  
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2.5.6 Synthesis of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-[2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 
6-(6-N-biotinylaminohexyl phosphate)], bistriethylammonium salt 47 
+
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Scheme 30 – Preparation of the protected biotinylated phosphosaccharide 47 
 
The condensation of the derivatives 28 and 46 (Scheme 30) was performed under 
standard condensation conditions, but with the addition of triethylamine during the 
condensation step. This was due to the fact that the biotin H-phosphonate derivative 28 is 
an acid and not the triethylammonium salt form. The reaction ran for 1 h and the product 
was then oxidised for 40 min. After the work-up and purification the protected biotin 
linked tetrasaccharide diphosphate 47 was isolated in a 79 % yield. The structure was 
confirmed through the 1H, 13C and 31P NMR data as well as the high resolution ES-MS 
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data. It can be seen very clearly in the 31P NMR spectrum (Fig 22) the two peaks at -4.39 
and -0.64 ppm. 
 
Fig 22 : 31P NMR spectrum of compound 47 
The peak seen at -0.64 ppm is the phosphate bridge between biotin and the last sugar 
unit. The peak at -4.39 ppm is very typical for the inter-saccharide phosphate signal, 
which is expected to be seen for the phosphate bridge between the disaccharide units. 
High resolution mass spec gave two pseudo-molecular ions for the protected biotin linked 
tetrasaccharide diphosphate 47, the first being at m/z 1206.2823 [M - 2Et3N - 2H]
2- and 
the other at m/z 2412.5840 [M - 2Et3N - H]
-. 
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2.5.7 Synthesis of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-{2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 
6-[2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-
mannopyranosyl phosphate]}, bistriethylammonium salt 48 
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Scheme 31 – Attempted coupling of the disaccharide H-phosphonate 36 and the tetrasaccharide 
monophosphate 46 
The formation of the protected hexasaccharide diphosphate derivative using the TBS 
protected disaccharide H-phosphonate 36 and the tetrasaccharide monophosphate 46 
(Scheme 31) was attempted many times under the normal condensation and oxidation 
conditions. The amount of the pivaloyl chloride and iodine were varied to try and help the 
reaction, but this had no success. The condensation with the TBS containing derivative 36 
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did not work, so it was decided to attempt a coupling using the DMT protected 
disaccharide H-phosphonate 34 (Scheme 32). The disaccharide H-phosphonate 34 was 
synthesised using the alternative strategy discussed in the Section 2.3.4.2. 
 
4634
O
OBz
BzO
BzO
ODMTr
O
O
OBz
OBz
O
BzO
H
P
O- +NHEt3
O
+
1. Pivaloyl chloride, Py
2. I2, Py/H2O (95:5)
O
OBz
BzO
BzO
O
OMe
OBz
OBz
O
BzOO
OBz
BzO
BzO
O
OBz
OBz
O
BzO
O
O
P
O- +NHEt3
O
OH
O
OBz
BzO
BzO
O
O
OBz
OBz
O
BzOO
OBz
BzO
BzO
O
OBz
OBz
O
BzO
O
O
P
O- +NHEt3
O
OH
O
OBz
BzO
BzO
O
OMe
OBz
OBz
O
BzO
O
P
O- +NHEt3
O
48
3. 1% TFA in CH2Cl2
 
Scheme 32 – Preparation of the hexasaccharide diphosphate 48 using the DMT protected disaccharide H-
phosphonate 34 
Using the DMT containing H-phosphonate 34 and the tetrasaccharide phosphate 46 the 
condensation was attempted under normal condensation and oxidation conditions. After 
2 h of condensation and 3 h of oxidation it could be seen by TLC that a new DMT product 
had been formed (DMT is very noticeable due to the orange colour given after acid 
visualisation of the TLC plate). After the work-up, the residue was dried and treated with 
1 % trifluoroacetic acid in DCM for 2 min at 0 oC to cleave the acid sensitive DMT 
87 
 
protecting group. The reaction mixture was worked-up and the residue was purified 
giving the hexasaccharide diphosphate 48 in a respectable 62 % yield. The structure was 
proved by 1H, 13C and 31P NMR data. In the 31P NMR spectrum it was possible to see both 
inter-saccharide phosphate signals at -4.47 and -4.38 ppm. High resolution mass 
spectrometry analysis also showed two pseudo-molecular ions at m/z 1517.8813 [M - 
2Et3N - 2H]
2- and 3035.8390 [M - 2Et3N - H]
-. 
The reason for the DMT derivative 34 working and the TBS derivative 36 not working in 
the condensation reaction with the tetrasaccharide phosphate 46 remains unknown. It 
could be to do with the size of the protecting groups and the effect this may have on the 
rest of the molecule. The DMT group is much larger compared with the TBS group and 
could influence the rest of the molecule somehow. 
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2.5.8 Synthesis of methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-{2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 
6-[2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-
mannopyranosyl phosphate 6-(6-N-biotinylaminohexyl phosphate)]}, 
tristriethylammonium salt 49 
The coupling of the biotin H-phosphonate 28 and the hexasaccharide diphosphate 48 was 
carried out in the normal condensation and oxidation conditions, with the addition of the 
triethylamine before (to convert compound 28 to the triethylammonium salt) before the 
pivaloyl chloride was added. After 2 h for the condensation step and 3 h for the oxidation 
step, it could be seen by TLC indicated the appearance of a strong new spot. 
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Scheme 33 – Preparation of the protected biotinylated phosphosaccharide 49 
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Work-up and purification gave the desired protected biotin linked hexasaccharide 
triphosphate 49 in a good yield of 64 %. The structure was proved by 1H, 13C and 31P NMR 
data. In the 13C NMR spectrum it was possible to see resonance signals for all the 
anomeric carbon atoms: 93.94 and 94.04 ppm (2 x br, C-1 Man’ & C-1 Man”), 98.35 ppm 
(C-1 Man), 101.03 ppm (C-1 Gal’), 101.22 and 101.27 ppm (C-1 Gal & C-1 Gal”). In the 31P 
NMR spectrum (Fig 23) three signals were seen at -4.66, -4.42 and -0.59 ppm, with the 
biotin-sugar phosphate linkage at -0.59 and the inter-saccharide phosphate linkages at -
4.66  and -4.42. This is the final of the targeted protected compounds to be successfully 
synthesised. 
 
Fig 23: 31P NMR spectrum of compound 49 
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2.5.9 Synthesis of methyl β-D-galactopyranosyl-(1→4)-α-D-
mannopyranoside 6-(6-N-biotinylaminohexyl phosphate), 
triethylammonium salt 50 (the first target compound) 
The full deprotection of compound 44 using sodium methoxide in methanol (to remove 
all the benzoate protecting groups) yielded the fully deprotected methyl β-D-
galactopyranosyl-(1→4)-α-D-mannopyranoside 6-(6-N-biotinylaminohexyl phosphate), 
triethylammonium salt 50 (95 %), i.e. the first target compound containing one repeat 
unit linked to biotin moiety (Scheme 27). 
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Scheme 34 – Preparation of the target compound 50 
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The structure was verified by 1H, 13C and 31P NMR. High resolution mass spec gave m/z 
760.2733 [M - Et3N - H]
- which confirmed the mass of the deprotected compound. 
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2.5.10 Synthesis of methyl β-D-galactopyranosyl-(1→4)-α-D-
mannopyranoside 6-[β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl 
phosphate 6-(6-N-biotinylaminohexyl phosphate)], bistriethylammonium 
salt 51 (the second target compound) 
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Scheme 35 – Preparation of the target compound 51 
 
The full deprotection of compound 47 using sodium methoxide in methanol (to remove 
all the benzoate protecting groups) yielded the fully deprotected methyl β-D-
galactopyranosyl-(1→4)-α-D-mannopyranoside 6-[β-D-galactopyranosyl-(1→4)-α-D-
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mannopyranosyl phosphate 6-(6-N-biotinylaminohexyl phosphate)], 
bistriethylammonium salt 51 (98 %), i.e. the second target compound containing two 
repeat units linked to biotin moiety (Scheme 35). The structure was verified by 1H, 13C and 
31P NMR. High resolution mass spec gave m/z 1164.3488 [M - 2Et3N - H]
- which confirmed 
the mass of the deprotected compound. 
 
 
 
 
 
 
 
 
 
 
2.5.11 Synthesis of methyl β-D-galactopyranosyl-(1→4)-α-D-
mannopyranoside 6-{β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl 
phosphate 6-[β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 
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6-(6-N-biotinylaminohexyl phosphate)]}, tristriethylammonium salt 52 (the 
third target compound) 
The full deprotection of compound 49 using sodium methoxide in methanol (to remove 
all the benzoate protecting groups) yielded the fully methyl  β-D-galactopyranosyl-(1→4)-
α-D-mannopyranoside 6-{β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 
6-[β-D-galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 6-(6-N-
biotinylaminohexyl phosphate)]}, tristriethylammonium salt 52 (90 %), i.e. the third target 
compound containing three repeat units linked to the biotin moiety (Scheme 36). The 
structure was verified by 1H, 13C and 31P NMR data. High resolution mass spec gave 
pseudo-molecular ions of m/z 1584.4125 [M - 3Et3N - H + NH3]
- and 1669.9165 [M - 2Et3N 
- H]- which confirmed the mass of the deprotected compound. 
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Scheme 36 – Preparation of the target compound 52 
 
 
 
 
 
 
 
2.6.0 Biological Results 
The deprotected target compounds (50 – 52) were then passed through to Prof. 
Mike Ferguson’s lab in Dundee, where PhD student Lauren Sullivan carried out the 
experiments using the compounds. The first set of experimental data that was 
needed was to measure the antibody binding to the synthetic repeat structures; this 
was done by using an ELISA assay. 
 
2.6.1 ELISA assay  
The assay was setup using a 48-well plate that was coated in a neutra-avidin to 
enable binding of the biotin in the final compounds. All 3 target compounds were 
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run against each other and against biotin. Biotin was used as a control and to block 
the neutra-avidin on the plate from any side reactions with the antibodies. The 
antibody used were the monoclonal IVD3 that recognises the repeat unit structure 
were added first. The anti-mouse IgG horseradish peroxidise (HRP) which binds the 
to the IVD3 antibody and when the HRP substrate is added and it gives out a 
chemiluminescence that is measured on an nVision spectrometer. An overview of 
the ELISA assay is shown below in Fig 27. 
 
 
Fig 27 – The ELISA assay 
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2.6.2 ELISA results 
The results from the ELISA assay can be seen in Figs 28 and 29. Two experiments 
were run in parallel, 1 was using an ascites sample and the other used purified IgG 
from the ascites. An ascites sample is the fluid from the peritoneal cavity of the 
animal in which the antibodies have been raised (in this case a mouse). The ascites 
contains a mixture of antibodies and many other things. This can be purified and the 
antibody need can be isolated, this is what was done to achieve pure IgG.  
 
Fig 28 – ELISA results of ascites dilution 
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Fig 29 – ELISA results of purified IgG 
It can be seen from the graphs that the compounds containing 1 or 2 repeat units did 
not perform well, with their signals similar to the pure biotin. The 3 repeat unit has a 
very good signal meaning there is antibody recognition and binding. The signal is 
much larger than the background or biotin only signal meaning there is very good 
interaction between the repeats and the antibody. This positive result from the 
compound containing 3 repeat units is very useful for the biochemical work and 
provides a foundation for further work. Now there is a synthetic phosphoglycan 
repeat unit with the biotin moiety attached providing the basis and possibility for 
further assay formations.  
The further work that will be carried out involves the comparison of this binding, 
during an inhibition assay, by using the same assay as before but with the addition of 
phosphoglycan (PG) fragments to see if the anchored compounds or the PG 
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fragments bind the antibodies. This will mimic what will happen when urine 
containing PG fragments is used. The experiment will show if plate bound PG repeats 
can be inhibited by free PG repeats. This work is ongoing in the Lab of Mike 
Ferguson.  
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3. EXPERIMENTAL 
 
 
 
 
 
 
3.1 General Procedures 
Melting points were determined on a Griffin melting point apparatus and are 
uncorrected.  Optical rotations were measured with a Perkin-Elmer 141 polarimeter; 
[α]D values are given in units of 10
-1 deg cm2 g-1. 1H, 13C and 31P NMR spectra were 
recorded with Bruker AVANCE 500 MHz spectrometer, unless otherwise indicated. 
Chemical shifts (δ in ppm) are given relative to those for Me4Si (for 
1H and 13C) and 
external aq. 85% H3PO4 (for 
31P); all J values are given in Hz.  ES mass spectra were 
recorded with a Mariner™ Biospectrometry Workstation and Aglient spectrometer. 
High resolution mass spectra were recorded on a Bruker microTOF. Thin layer 
chromatography (TLC) was performed on Kieselgel 60 F254 (silica gel) aluminium 
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plates (Merck) with A, toluene-ethyl acetate (9:1); B, toluene-methanol (7:3); C, 
toluene-ethyl acetate (95:5); D, toluene-ethyl acetate (7:3); E, toluene-ethyl acetate 
(75:25); F, petroleum ether (40-60 oC)-ethyl acetate (6:4); G, toluene-ethyl acetate 
(8:2); H, dichloromethane-methanol (9:1) as developers, followed by detection 
under UV light and/or by charring, which was carried out with sulphuric acid-water-
ethanol (15:85:5) for protected compounds or a mixture of orcinol containing 
sulphuric acid-ethanol-water (10:75:5) for final deprotected compounds. Flash 
column chromatography (FCC) was performed on Kieselgel 60 (0.040-0.063 mm) 
(Merck), unless otherwise indicated. Dichloromethane, acetonitrile, pyridine and 
toluene were freshly distilled from CaH2.  Petroleum ether refers to that with boiling 
fraction 40-60 oC, unless otherwise stated.  Solutions worked up were concentrated 
under reduced pressure at < 40 oC. 
1,2,3,6-Tetra-O-benzoyl-α-D-mannopyranose 21  
 
D-Mannose (3.6 g, 20 mmol) was dissolved in pyridine (25 ml) and the solution was 
stirred and cooled to -40 oC. Benzoyl chloride (9.27 ml, 80 mmol) in pyridine (15 ml) 
was added dropwise over 40 minutes.  Once the addition was complete the mixture 
was allowed to warm to room temperature. After 1 h TLC (Solvent A) showed that 
the reaction was complete. The reaction was quenched by addition of water (100 
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ml), the mixture was stirred for 1 h, prior it was diluted with CH2Cl2 (200 ml). The 
organic layer was separated and washed successively with 1M HCl, water and 
saturated aq. NaHCO3, dried (MgSO4) and concentrated. The residue was dissolved in 
ethanol (100 ml), and kept at 4 oC overnight. The crystals were filtered off and 
mother liquor was removed. Dried crystals were dissolved in ethyl acetate with 
heating and n-hexane was added slowly over 10 min. The mixture was cooled and 
was placed at 4 oC for 16 h.  The mother liquid was removed and the crystals were 
dried. The crystals were desired protected compound 21 (5.72 g, 9.58 mmol, 48%). 
Mp 184-185 oC; literature data [99] mp 183-184 oC. 
[ ]20Dα +19.5 (c 1, CHCl3); literature data 
[99] [ ]20Dα +41 (c 1, CHCl3). 
1H NMR (CDCl3): δH 3.24 (1H, d, J4,OH 5.0, 4-OH), 4.25(1H, ddd, J5,6a 2.2, H-5), 4.38 (1H, 
dt, J3,4 = J4,5 = 10.2, H-4), 4.52 (1H, dd, J6a,6b 12.4, H-6a), 5.02 (1H, dd, J5,6b 2.8, H-6b), 
5.82 (2H, m, H-2 & H-3), 6.56 (1H, d, J1,2 1.5, H-1) and 7.24-8.20 (20H, m, 4 x Ph). 
13C NMR (CDCl3): δc 62.81 (C-6), 65.38 (C-4), 69.39 (C-2), 71.93 (C-3), 73.76 (C-5), 
91.46 (C-1), 128.42-133.54 (Ph) and 164.76-165.12(C=O). 
High resolution ES-MS(+): found m/z 614.2012 [M + NH4]
+ (C34H28O10
 requires M: 
596.1682; C34H32NO10
+ requires m/z 614.2021) and 619.1564 [M + Na]+ (C34H28NaO10
+ 
requires m/z 619.1575). 
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1,2,3,4-Tetra-O-benzoyl-6-O-tert-butyldimethylsilyl-α,β-D-
galactopyranose 22 
  
D-Galactose (1 g, 5.56 mmol) was dissolved in pyridine (15 ml), and the solution was 
cooled to 0 oC. tert-Butyldimethylsilyl chloride (1.09 g, 7.22 mmol) was added, and 
the reaction was monitored by TLC (Solvent B). After 2 h, benzoyl chloride (5.15 ml, 
44.4 mmol) was added dropwise to the cooled solution. After a further 14 h, TLC 
(Solvent C) showed complete benzoylation. Water (25 ml) was added and the 
reaction mixture was left to stir for 1 h. The mixture was diluted with CH2Cl2, and 
washed successively with 1M HCl, water and saturated aq. NaHCO3, dried (MgSO4) 
and concentrated. FCC [toluene-ethyl acetate (95:5)] of the residue gave compound 
22 (3.25 g, 4.576 mmol, 82 %) as a white foam. 
[ ]20Dα +34.5 (c 1, CHCl3). 
1H NMR (CDCl3): δH -0.07, -0.06, -0.02, 0.00 (4 x s, CH3Si), 0.83, 0.85 (2 x s, tert-Bu), 
3.80-3.97 (m, H-6a &H-6b), 4.30 (ddd, J5β,6aβ 1.5, J5β,6bβ 5.5, H-5β), 4.55 (dt, J5α,6α 6.9, 
H-5α), 5.81 (dd, J3β,4β 3.5, H-3β), 6.00 (dd, J3α,4α 3.7, H-3α), 6.08 (dd, J2β,3β 10.3, H-
2β), 6.10 (dd, J4β,5β 0.9, H-4β), 6.16 (dd, J2α,3α 10.4, H-2α) 6.18 (dd, J4α,5α 1.1, H-4α), 
6.25 (d, J1β,2β 8.3, H-1β), 6.93 (d, J1α,2α 3.6, H-1α) and 7.20-8.30 (m, Ph); α:β = 3:4.  
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13C NMR (CDCl3): δc -5.72, -5.67 (CH3Si), 18.01 (Me3C), 25.63, 25.72 (Me3C), 60.31 (C-
6β), 60.62 (C-6α), 67.53, 67.98, 68.18, 68.82, 68.99, 61.91 (C-2α, C-3α, C-4α, C-5α, 
C-2β & C-4β), 71.80 (C-3β), 74.85 (C-5β), 90.69 (C-1α), 93.22 (C-1β), 128.16-134.60 
(Ph) and 165.49-166.13 (C=O). 
High resolution ES-MS(+): found m/z 733.2445 [M + Na]+ (C40H42O10Si
 requires M: 
710.2547; C40H42NaO10Si
+ requires m/z 733.2439). 
 
 
 
2,3,4-Tri-O-benzoyl-6-O-tert-butyldimethylsilyl-α,β-D-galactopyranose 
23 
  
Method A 
 Compound 22 (2 g, 2.82 mmol) was dissolved in THF (5 ml) and 2M dimethylamine 
in tetrahydrofuran (20 ml, 40 mmol) was added. This was stirred with monitoring by 
TLC (Solvent C). After 12 h (22 was not consumed completely), the mixture was 
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concentrated to dryness.  FFC [toluene-ethyl acetate (98:2→95:5)] of the residue 
yielded the hemiacetal 23 (1 g, 1.65 mmol, 59 %). 
Method B 
Acetic acid (81 µl, 1.41 mmol) was added dropwise to a stirring solution of 
ethylenediamine (190 µl, 2.85 mmol) in THF (25 ml). This instantly formed a white 
precipitate. The protected derivative 22 (1 g, 1.41 mmol) was added and the reaction 
mixture was left for 30 h. TLC (Sovlent C) showed the reaction was complete. Water 
was added and, after 10 min, the reaction mixture was diluted with CH2Cl2 and 
washed successively with 1M HCl, water and saturated aq. NaHCO3, dried (MgSO4) 
and concentrated. FCC [toluene-ethyl acetate (98:2)] of the residue yielded the 
hemiacetal 23 (650 mg, 1.07 mmol, 75 %) as an amorphous solid. 
[ ]20Dα +14.2 (c 1, CHCl3). 
1H NMR (CDCl3): δH -0.13, -0.08, 0.00 (3 x s, CH3Si), 0.75, 0.77 (2 x s, tert-Bu), 3.64-
3.81 (m, H-6α & H-6β), 3.97 (ddd, J5β,6aβ 6.8, J5β,6bβ 7.9, H-5β), 4.50 (dt, J5α,6α 7.2, H-
5α), 4.92 (d, J1β,2β 7.9, H-1β), 5.47 (dd, J2β,3β 10.3, H-2β),5.56 (dd, J2α,3α 10.6, H-2α), 
5.64 (dd, J3β,4β 3.5, H-3β), 5.73 (d, J1α,2α 3.6, H-1α), 5.89 (dd, J4β,5β 0.8, H-4β), 5.92 
(dd, J4α,5α 1.1, H-4α), 5.97 (dd, J3α,4α 3.4, H-3α),  and 7.15-8.05 (m, Ph); α:β = 5:2. 
13C NMR (CDCl3): δc -5.68, -5.58 (CH3Si), 18.01 (Me3C), 25.81 (Me3C), 60.59 (C-6β), 
61.25 (C-6α), 67.76, 68.28, 68.97, 69.43, 69.84 (C-2α, C-3α, C-4α, C-5α, C-2β & C-
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4β), 71.19 (C-3β), 74.23 (C-5β), 91.04 (C-1α), 96.36 (C-1β), 128.22-133.67 (Ph) and 
165.49-166.13 (C=O). 
High resolution ES-MS(+): found m/z 629.2183 [M + Na]+ (C33H38O9Si
 requires M: 
606.2285; C33H38NaO9Si
+ requires m/z 629.2177). 
 
 
 
 
2,3,4-Tri-O-benzoyl-6-O-tert-butyldimethylsilyl-α-D-galactopyranosyl 
trichloroacetimidate 24 
 
Compound 23 (583 mg, 0.981 mmol) was dissolved in CH2Cl2 (4 ml), the solution 
cooled to 0 oC while trichloroacetonitrile (964 µl, 9.61 mmol) and Cs2CO3 (cat.) were 
respectively added. After 1 h monitoring by TLC (Solvent C) showed one product and 
no starting material left. The mixture was diluted with CH2Cl2, filtered through celite 
and concentrated to dryness. FCC [toluene-ethyl acetate (98:2→95:5)] of the residue 
gave the trichloroacetimidate 24 (379 mg, 0.625 mmol, 64 %) as an amorphous solid. 
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[ ]20Dα +42.8 (c 1, CHCl3). 
1H NMR (CDCl3): δH 0.00, 0.05 (6H, 2 x s, CH3Si), 0.90 (9H, s, tert-Bu), 3.84 (1H, dd, 
J5,6a 7.7, H-6a), 3.90 (1H, dd, J6a,6b 10.1, H-6b), 4.59(1H, ddd, J5,6b 6.1, H-5), 5.96 (1H, 
dd, J2,3 10.6, H-2), 6.14 (1H, dd, J3,4 3.3, H-3), 6.18  (1H, dd, J4,5 1.2 H-4), 6.94 (1H, d, 
J1,2 3.7, H-1), 7.24-8.18 (15H, m, Ph) and 8.69 (1H, s, NH). 
13C NMR (CDCl3): δc -5.65, -5.59 (CH3Si), 18.01 (Me3C), 25.74 (Me3C), 60.82 (C-6), 
68.21, 68.59, 72.22 (C-2, C-3, C-4 & C-5), 93.93 (C-1), 128.28-133.48(Ph) and 165.49-
166.13 (C=O). 
High resolution ES-MS(+): found m/z 605.2132 [M - CNHCCl3]
+ (C35H38Cl3NO10Si
 
requires M: 749.1381; C33H37O8Si
+ requires m/z 605.2212 ). 
 
 
Methyl 2,3,6-tri-O-benzoyl-α-D-mannopyranoside 25 
 
Methyl α-D-mannopyranoside (1.5 g, 7.7 mmol) was dissolved in pyridine (30 ml) 
and the solution was cooled to -40 oC. Benzoyl chloride (3.48 g, 24.7 mmol) in 
pyridine (20 ml) was added dropwise over 1 h and the mixture was left for 20 h at rt. 
Water was added, the mixture was stirred for 2 h prior it was diluted with CH2Cl2. 
108 
 
The organic layer was washed successively with 1M HCl, water and saturated aq. 
NaHCO3, dried (MgSO4) and concentrated. FFC [toluene-ethyl acetate (99:1→90:10)] 
of the residue gave the protected monosaccharide 25 (2.75 g, 5.43 mmol, 71 %) as a 
white foam. 
[ ]20Dα +19.3 (c 1, CHCl3).  
1H NMR (CDCl3): δH 3.50 (3H, s, OMe), 4.12 (1H, ddd, J5,6a 2.8, H-5), 4.31 (1H, t, J3,4 = 
J4,5 = 9.5), 4.67 (1H, dd, J6a,6b 12.1, H-6a), 4.93 (1H, dd, J5,6b 3.9, H-6b), 4.96 (1H, d, J1,2 
1.0, H-1), 5.63-5.67 (2H, m, H-2 & H-3) and 7.20-8.17 (15H, m, Ph). 
13C NMR (CDCl3): δc 55.39 (OMe), 63.40 (C-6), 63.34 (C-4), 70.47 (C-2), 71.19 (C-5), 
72.63 (C-3), 98.70 (C-1), 128.25-133.41 (Ph) and 166.73-166.96 (C=O). 
High resolution ES-MS(+): found m/z 507.1653 [M + H]+ (C28H26O9
 requires M: 
506.1577; C28H27O9
+ requires m/z 507.1650) and 529.1483 [M + Na]+ (C28H27NaO9
+ 
requires m/z 529.1469). 
 
 
109 
 
D-Biotin p-nitrophenyl ester 26 
 
D-Biotin (200 mg, 0.82 mmol) was added to pyridine (5 ml) under stirring. p-
Nitrophenyl trifluoroacetate (731 mg, 3.11 mmol) and p-nitrophenol (103 mg, 0.74 
mmol) where added to the suspension. The mixture was stirred at 55 oC for 2 h and 
evaporated to dryness. The dried residue was collected and washed with Et2O (3 
times) to remove excessive p-nitrophenol. The filtrate was recrystallised from 
ethanol, the crystals were harvested and dried under vaccum. This gave the biotin 
ester 26 (210 mg, 0.57 mmol, 72 %) as crystals. 
Mp 164-165 oC. 
[ ]20Dα +22.1 (c 1, MeOH). 
1HNMR (CDCl3): δH  1.37-1.45 (2H, m, CH2), 1.52-1.71 (4H, m, 2 x CH2), 2.49 (2H, t, J 
7.4, CH2CO), 2.65 (1H, br d, Ja,b 13.0, H
b), 2.80 (1H, dd, Ja,c 5.0, H
a), 3.06 (1H, m, He), 
4.24 (1H, dd, Jc,d 7.8, Jd,e 4.5, H
d), 4.44 (1H, m, Hc) and 7.13-8.14 (4H, m, C6H4). 
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13C NMR [(CD3)2SO]: δc 24.15, 27.85, 27.94 (3 x CH2), 33.25 (CH2CO), 39.81 (C
ab), 
55.27 (Ce), 59.23 (Cc), 61.02 (Cd), 123.16, 125.24, 144.95, 155.37 (C6H4), 162.73 
(NHCONH) and 171.14 (CH2COO). 
High resolution ES-MS(+): found m/z 366.1110 [M + H]+ (C16H19N3O5S
 requires M: 
365.1045; C16H20N3O5S
+ requires m/z 366.1118). 
 
 
 
 
6-N-Biotinylaminohexanol 27 
 
Compound 26 (500 mg, 1.37 mmol) and 6-aminohexanol (161 mg, 1.37 mmol) were 
added to DMSO (5 ml) and the solution was stirred for 20 h. The reaction was 
stopped by pouring the solution into a mixture of acetone (10 ml) and Et2O (16 ml). 
The resultant suspension was placed in the fridge overnight. The precipitate was 
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filtered off and washed with Et2O (4x). This gave the modified biotin derivative 27 
(392 mg, 1.01 mmol, 80%) as an amorphous solid. 
[ ]20Dα +12.6 (c 1, MeOH). 
1HNMR [(CD3)2SO]: δH 1.20 -1.65(14H, m, 7 x CH2), 2.04 (2H, t, J 7.4, CH2CO), 2.58 
(1H, br d, Ja,b 12.4, H
b), 2.82 (1H, dd, Ja,c 5.1, H
a), 3.00 (2H, q, J 6.5, CH2N), 3.09 (1H, 
m, He), 3.37 (2H, dt, JH,H 6.5, JH,OH 5.2, CH2OH), 4.13 (1H, m, H
d), 4.31 (1H, m, Hc), 4.36 
(1H, t, JH,OH 5.2, CH2OH), 6.38 (1H, br, NH) 6.45 (1H, br, NH) and 7.75 (1H, t, J 5.5 
CH2NH). 
13C NMR [(CD3)2SO]: δc 25.23, 25.32, 26.32, 28.01, 28.19, 29.22 (6 x CH2), 32.47 
(CH2CH2OH), 35.18 (CH2CO), 38.32 (CH2N), 39.82 (C
ab), 55.42 (Ce), 59.13 (Cc), 60.63 
(CH2OH), 61.00 (C
d), 162.68 (NHCONH) and 171.75 (CH2CONH). 
High resolution ES-MS(+): found m/z 344.2006 [M + H]+ (C16H29N3O3S
 requires M: 
343.1930; C16H30N3O3S
+ requires m/z 344.2002). 
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6-N-Biotinylaminohexyl hydrogenphosphonate 28 
 
Compound 27 (100 mg, 0.29 mmol) was dissolved in a mixture of DMF (5 ml) and 
pyridine (60 µl). A solution of salicyl chlorophosphite (76 mg, 0.38 mmol) in DMF 
(5ml) was added dropwise over 10 min to the stirred solution. After a further 10 min, 
1M TEAB buffer (0.5 ml) was added and the mixture left for 15 min. Et2O (55 ml) was 
then added and the mixture was placed in the fridge for 16 h. The precipitate that 
had formed was filtered off, washed with Et2O (3 x 30 ml) and CH2Cl2 (3 x 30 ml) and 
dried under vacuum. This gave the biotinylaminohexyl hydrogenphosphonate 28 
(106 mg, 0.261 mmol, 90 %) as an amorphous solid. 
[ ]20Dα +19.1 (c 1, MeOH). 
1H NMR (CD3OD): δH 1.34-1.77 (14H, m, 7 x CH2), 2.28 (2H, t, J 7.4, CH2CO), 2.70 (1H, 
d, Ja,b 12.1, H
b), 2.92 (1H, dd, Ja,c 4.0, H
a), 3.15-3.23 (3H, m, He & CH2N), 4.01 (2H, dt, 
JH,P 8.4, JH,H 6.5, CH2OP), 4.30 (1H, dd, Jd,e 4.5, H
d), 4.49 (1H, dd, Jc,d 7.8, H
C) and 6.76 
(1H, d, JH,P 680.8, HP). 
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13C NMR (CD3OD): δc 26.36, 26.95, 27.49, 29.53, 29.79, 30.32 (6 x CH2), 31.45 (d, 
3
JC,P 
6.5, CH2CH2OP), 36.84 (CH2CO), 40.25 (CH2N), 41.04 (C
ab), 57.03 (Ce), 61.68 (Cc), 
63.45 (Cd), 66.31 (d, 2JC,P 5.1, CH2OP), 166.13 (NHCONH) and 176.02 (CH2CONH). 
High resolution ES-MS(+): found m/z 408.1722 [M + H]+ (C16H30N3O5PS
 requires M: 
407.1644; C16H31N3O5PS
+ requires m/z 408.1717). 
 
 
2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl trichloroacetimidate 29 
 
Penta-O-acetyl-β-D-galactopyranose (1.2 g, 3.07 mmol) was dissolved in MeCN (10 
ml), to this mixture 2M dimethylamine in tetrahydrofuran (8 ml, 16 mmol) was 
added and the solution left at rt for 1 h. Monitoring by TLC (Solvent D) showed one 
major product (thought to be 2,3,4,6-tetra-O-acetyl-D-galactopyranose). The 
solution was evaporated to dryness, the residue was dissolved in CH2Cl2, washed 
with water (3 x 50 ml), dried (MgSO4) and concentrated. The residue was dissolved in 
CH2Cl2 (10 ml), the solution was cooled to 0 
oC and trichloroacetonitrile (3.07 ml, 
30.7 mmol) and Cs2CO3 (cat.) were added under stirring. After 2 h, monitoring by TLC 
(Solvent D) showed the reaction was complete. The mixture was diluted with CH2Cl2, 
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filtered through a Celite pad and the filtrate was concentrated. FCC [toluene-ethyl 
acetate (1:99→12:88)] of the residue gave the trichloroacetimidate 29 (1.21 g, 2.45 
mmol, 80 %) as an amorphous solid. 
[ ]20Dα +23.6 (c 1, CHCl3). 
1H NMR (CDCl3): δH 2.03-2.06 (9H, m, 3 x Ac), 2.19 (3H, s, Ac), 4.11 (1H, dd, J6a,6b 11.3, 
J6a,5 6.7, H-6a), 4.19 (1H, dd, J6b,5 6.7, H-6b), 4.46 (1H, dt, J5,4 0.7, H-5), 5.37 (1H, dd, 
J2,3 10.8, H-2), 5.44 (1H,dd, J3,4 3.4, H-3), 5.58 (1H, dd, H-4), 6.63 (1H, d, J1,2 3.4, H-1) 
and 8.69 (1H, s, NH). 
13C NMR (CDCl3): δc 20.50, 20.58 (CH3), 61.20 (C-6), 66.85 (C-2), 67.32 (C-4), 67.45 (C-
3), 68.94 (C-5), 90.72 (CCl3), 93.48 (C-1), 160.88 (C=NH) and 169.91-170.23 (C=O). 
Low resolution ES-MS(+): found m/z 514.00 [M + Na]+ (C16H20 Cl3N3O10
 requires 
M:491.02; C16H20 Cl3N3NaO10
+  requires m/z 514.0045). 
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1,2,3,6-Tetra-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-
butyldimethylsilyl-β-D-galactopyranosyl)-α-D-mannopyranose 30 
 
A mixture of compounds 24 (650 mg, 0.865 mmol) and 21 (430 mg, 0.721 mmol) was 
dissolved in freshly distilled CH2Cl2 (3 ml), before freshly activated molecular sieves 
4Å (500 mg) were added. This suspension was cooled to -30 oC under stirring and 
trimethylsilyl trifluoromethanesulfonate (39 µl, 0.216 mmol) was injected through 
the septa. Monitoring by TLC (Solvent C) showed that after 30 minutes the glycosyl 
donor 24 was consumed. The reaction was stopped by adding triethylamine (100 µl) 
in CH2Cl2 (1ml) and left for 10 min. The mixture was diluted with CH2Cl2, filtered 
through a Celite pad to remove solids and the filtrate was concentrated. FCC 
[toluene-ethyl acetate (100:0→95:5)] of the residue gave the protected disaccharide 
30 (738 mg, 0.623 mmol, 72 %) as an amorphous solid. 
[ ]20Dα +36.8 (c 1, CHCl3). 
1H NMR (CDCl3): δH -0.10 (3H, s, CH3Si), -0.01 (3H, s, CH3Si), 0.93 (9H, s, tert-Bu), 3.40-
3.48 (2H, m, H-6b’ & H-6a’), 3.78 (1H, ddd, J5’,6a’ 5.5, J5’,6b’ 9.1, H-5’), 4.49 (1H, ddd, 
J5,6a 2.8, H-5), 4.73 (1H, dd, J6a,6b 12.2, H-6a), 4.87 (1H, dd, J5,6b 2.0, H-6b), 4.89 (1H, t, 
J3,4 = J4,5 =  9.6, H-4), 5.22 (1H, d, J1’,2’ 7.9 H-1’), 5.69 (1H, ddd, J3’,4’ 3.3, H-3’), 5.93 (1H, 
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dd, J2’,3’ 10.4, H-2’), 5.98 (1H, dd, J4’,5’ 0.8, H-4’), 6.07 (1H, dd, J2,3 3.4, H-2), 6.22 (1H, 
dd, H-3), 6.72 (1H, d, J1,2 2.0, H-1) and 7.38-8.40 (35H, m, Ph). 
13C NMR (CDCl3): δc -5.80, -5.66 (2 x CH3Si), 18.17 (Me3C), 25.63 (Me3C), 59.32 (C-6’), 
61.77 (C-6), 67.01 (C-4’), 69.39 (C-2), 70.36 (C-2’), 70.60 (C-3), 71.61 (C-5), 71.96 (C-
3’), 73.40 (C-4), 73.56 (C-5’), 91.30 (C-1), 101.72 (C-1’), 128.21-134.13 (Ph) and 
163.97-165.51 (C=O). 
High resolution ES-MS(+): found m/z 1207.3760 [M + Na]+ (C67H64O18Si
 requires M: 
1184.3862; C67H64NaO18Si
+ requires m/z 1207.3754). 
 
 
1,2,3,6-Tetra-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl)-α-D-mannopyranose 31 
 
Acetonitrile (2 ml) was used to dissolve the disaccharide 30 (500 mg, 0.423 mmol), 
and the solution was cooled to 0 oC. A mixture of 40 % aq. HF and MeCN (1:1, 2 ml) 
was added under stirring. This gave a resultant concentration of 10 % HF in the 
reaction mixture. The reaction was run for 3 h and monitored by TLC (Solvent E). To 
stop the reaction saturated aq. NaHCO3 was added dropwise to the mixture until the 
117 
 
bubbling stopped. The mixture was diluted with CH2Cl2 (150 ml), washed with water 
(5 x 40 ml), dried (MgSO4) and concentrated. A solution of the residue in CH2Cl2 was 
filtered through a silica gel pad and concentrated to dryness. This gave the 
disaccharide 31 (430 mg, 0.402 mmol, 95 %) as an amorphous solid. 
1H NMR (CDCl3): δH 3.09 (1H, dd, J6a’,6b’ 11.9 H-6a’), 3.20 (1H, dd, J5’,6b’ 6.3, H-6b’) 3.65 
(1H, dd, J 5’,6a’ 7.6, H-5’), 4.31 (1H, ddd, J5,6a 2.9, H-5), 4.54 (1H, dd, J6a,6b 12.3, H-6a), 
4.67 (1H, dd, J5,6b 1.7, H-6b), 4.71 (1H, t, J3,4 = J4,5 =  9.4, H-4), 5.04 (1H, d, J1’,2’ 7.9 H-
1’), 5.46 (1H, dd, J2’,3’ 10.4, H-3’), 5.64 (1H, d, J3’,4’ 3.3, H-4’), 5.87 (2H, m, H-2 & H-2’), 
6.06 (1H, dd, J2,3 3.4, H-3), 6.56 (1H, d, J1,2 2.3, H-1) and 7.12 -8.24 (35H, m, Ph). 
13C NMR (CDCl3): δc 59.89 (C-6’), 61.92 (C-6), 68.53 (C-4’), 69.63 (C-2), 70.12(C-3), 
70.18 (C-2’), 71.59 (C-5), 71.83 (C-3’), 73.56 (C-4), 74.13 (C-5’) 91.32 (C-1), 101.49 (C-
1’), 128.25-134.02 (Ph) and 164.06-166.67 (C=O). 
High resolution ES-MS(+): found m/z 1093.2895 [M + Na]+ (C61H50O18 requires M: 
1070.2997; C61H50NaO18
+ requires m/z 1093.2889). 
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1,2,3,6-Tetra-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-
dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranose 32 
(Method A) 
 
Compound 31 (600 mg, 0.56 mmol) was dissolved in pyridine (3 ml), and the solution 
was cooled to 0 oC. p,p′-Dimethoxytriphenylmethyl chloride (474 mg, 1.4 mmol) was 
added and the reaction mixture was left for 15 h at rt. Monitoring by TLC (Solvent F) 
showed the reaction was complete. The mixture was diluted with CH2Cl2, washed 
with water (2 x 50 ml), dried by filtration through cotton wool, concentrated and 
toluene was evaporated off the residue. FCC [toluene-ethyl acetate (80:20→70:30)] 
of the residue provided the protected disaccharide 32 (630 mg, 0.46 mmol, 82 %). 
Compound 12 was later prepared in an alternative way from the disaccharide 
derivative 39. 
[ ]20Dα +62.7 (c 1, CHCl3). 
1H NMR (CDCl3): δH 3.02 (1H, t, J5’,6a’ = J6a’,6b’ = 9.0, H-6a’), 3.15 (1H, dd, J5’,6b’ 5.1, H-
6b’), 3.56, 3,57  (6H, 2 x s, 2 x OMe), 3.73 (1H, br dd, H-5’), 4.07 (1H, ddd, J5,6a 1.8, H-
5), 4.44 (1H, dd, J6a,6b 12.1, H-6a), 4.49 (1H, dd, J5,6b 3.1, H-6b), 4.56 (1H, t, J3,4 = J4,5 = 
9.7, H-4), 4.88(1H, d, J1’,2’ 7.8, H-1’), 5.40 (1H, dd, J2’,3’ 10.3, H-3’), 5.55 (1H, dd, H-2’), 
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5.73 (1H, dd, H-2), 5.79 (1H, dd, J2,3 3.3, H-3), 5.91 (1H, br d, J3’,4’ 2.9, H-4’), 6.40 (1H, 
d, J1,2 2.0, H-1) and 6.46-8.20 (48H, m, C6H4 & Ph). 
13C NMR (CDCl3): δc 55.03 (OMe), 59.52 (C-6’), 62.07 (C-6), 67.52 (C-4’), 69.58 (C-2), 
70.10 (C-3), 70.24 (C-2’), 71.95 (C-5), 72.10 (C-3’), 72.56 (C-5’), 72.65 (C-4), 86.25 
(Ar3C), 91.19 (C-1), 101.39 (C-1’), 113.00, 126.75-135.65,143.97, 158.27, 158.39 (C6H6 
and Ph) and 163.96-165.67 (C=O). 
High Resolution ES-MS(+): found m/z 1395.4202 [M+Na]+ (C82H68O20 requires M: 
1372.4304; C82H68NaO20
+ requires m/z 1395.4196 ). 
 
 
1,2,3,6-Tetra-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-
dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranose 32  
(Method B) 
 
A solution of HCl in MeOH [prepared at 0 oC from acetyl chloride (0.2 ml) and 
methanol (5 ml)] was added to a solution of compound 39 (600 mg, 0.55 mmol) in 
CH2Cl2 (2 ml) and the mixture was stirred at rt for 20 h. Checking by TLC (solvent H) 
showed that there was one major product, thought to be the deacetylated 
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compound. The reaction mixture was diluted with CH2Cl2 and washed successively 
with saturated aq. NaHCO3 (twice) and water (twice), dried by filtration through 
cotton wool and concentrated. The residue was dissolved in pyridine (10 ml), p,p’-
dimethoxytriphenylmethyl chloride (560 mg, 1.65 mmol) was added and the solution 
was left stirring at rt for 20 h. Benzoyl chloride (510 µl, 4.4 mmol) was then added at 
-10 oC and the mixture was stirred at rt for 15 h. TLC (solvent A) showed that the 
benzoylation had been completed. The reaction mixture was diluted with CHCl3 and 
washed successively with saturated aq. NaHCO3 (twice) and water (twice), dried by 
filtration through cotton wool and concentrated. FFC [toluene-ethyl acetate 
(100:0→90:10)] of the residue gave the disaccharide 32 (546 mg, 0.398 mmol, 91%) 
as an a amorphous solid. 
[ ]20Dα +62.7 (c 1, CHCl3). 
1H NMR (CDCl3): δH 3.02 (1H, t, J5’,6a’ = J6a’,6b’ = 9.0, H-6a’), 3.15 (1H, dd, J5’,6b’ 5.1, H-
6b’), 3.56, 3,57  (6H, 2 x s, 2 x OMe), 3.73 (1H, br dd, H-5’), 4.07 (1H, ddd, J5,6a 1.8, H-
5), 4.44 (1H, dd, J6a,6b 12.1, H-6a), 4.49 (1H, dd, J5,6b 3.1, H-6b), 4.56 (1H, t, J3,4 = J4,5 = 
9.7, H-4), 4.88(1H, d, J1’,2’ 7.8, H-1’), 5.40 (1H, dd, J2’,3’ 10.3, H-3’), 5.55 (1H, dd, H-2’), 
5.73 (1H, dd, H-2), 5.79 (1H, dd, J2,3 3.3, H-3), 5.91 (1H, br d, J3’,4’ 2.9, H-4’), 6.40 (1H, 
d, J1,2 2.0, H-1) and 6.46-8.20 (48H, m, C6H4 & Ph). 
13C NMR (CDCl3): δc 55.03 (OMe), 59.52 (C-6’), 62.07 (C-6), 67.52 (C-4’), 69.58 (C-2), 
70.10 (C-3), 70.24 (C-2’), 71.95 (C-5), 72.10 (C-3’), 72.56 (C-5’), 72.65 (C-4), 86.25 
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(Ar3C), 91.19 (C-1), 101.39 (C-1’), 113.00, 126.75-135.65,143.97, 158.27, 158.39 (C6H6 
and Ph) and 163.96-165.67 (C=O). 
High Resolution ES-MS(+): found m/z 1395.4202 [M+Na]+ (C82H68O20 requires M: 
1372.4304; C82H68NaO20
+ requires m/z 1395.4196 ). 
 
 
2,3,6-Tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-dimethoxytrityl)-
β-D-galactopyranosyl]-α-D-mannopyranose 33 
 
Method A 
Compound 32 (292 mg, 0.22 mmol) was dissolved in THF (2 ml), and 2M 
dimethylamine in tetrahydrofuran (2 ml, 4 mmol) was added. This was stirred at rt 
for 20 h with monitoring by TLC (Solvent G). The mixture was concentrated to 
dryness. FFC [toluene-ethyl acetate (90:10→80:20)] of the residue yielded the 
hemiacetal derivative 33 (200 mg, 0.14 mmol, 70 %) as an amorphous solid. 
Method B 
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Acetic acid (101 µl, 1.77 mmol) was added drop wise to a stirring solution of 
ethylenediamine (236 µl, 3.54 mmol) in THF (4 ml). This instantly formed a white 
precipitate. The protected disaccharide 32 (250 mg, 1.77 mmol) was added and the 
reaction mixture and left for 40 h under stirring. TLC (Sovlent G) showed the reaction 
was complete. Water was added and, after 10 minutes, the mixture was diluted with 
CH2Cl2 and washed successively with 1M HCl, water and saturated aq. NaHCO3, dried 
(MgSO4) and concentrated. FCC [toluene-ethyl acetate (85:15)] of the residue 
yielded the anomerically deprotected disaccrharide 33 (650 mg, 1.07 mmol, 75 %) as 
an amorphous solid. 
[ ]20Dα +56.1 (c 1, CHCl3). 
1H NMR (CDCl3): δH 3.05 (1H, m, H-6a’), 3.17 (1H, dd, J6a’,6b’ 8.8, H-6b’), 3.55, 3.56 (6H, 
2 x s, 2 x MeO), 3.66 (1H, br dd, J5’,6a’ 8.9, J5’,6b’ 5.1, H-5’), 4.20 (1H, dd, J4,5 9.8, J5,6a 
2.3, H-5), 4.44 (2H, m, H-4 & H-6a), 4.52 (1H, dd, J5,6b 1.3, J6a,6b 12.0, H-6b), 4.84 (1H, 
d, J1’,2’ 7.9, H-1’), 5.21 (1H, d, J1,2 1.5, H-1), 5.38 (1H, dd, J2’,3’ 10.4, H-3’), 5.53 (2H, m, 
H-2 & H-2’), 5.73 (1H, dd, J2,3 3.3, J3,4 9.6, H-3), 5.87 (1H, br d, H-4’) and 6.47-7.90 
(43H, m, C6H4 & Ph). 
13C NMR (CDCl3): δc 55.10 (OMe), 59.61 (C-6’), 62.67 (C-6), 67.58 (C-4’), 69.43 (C-5), 
69.83 (C-3), 70.26 (C-2’), 71.19 (C-2), 71.85 (C-3’), 72.44 (C-5’), 73.07 (C-4), 86.27 
(Ar3C), 92.02 (C-1), 100.98 (C-1’), 113.03, 128.19-133.30, 144.08, 158.30, 158.38 
(C6H4 & Ph) and 164.97-166.04 (C=0). 
 
123 
 
2,3,6-Tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-(p,p’-dimethoxytrityl)-
β-D-galactopyranosyl]-α-D-mannopyranosyl hydrogenphosphonate, 
triethylammonium salt 34 
 
 
Method A 
To a stirred solution of imidazole (157 mg, 2.30 mmol) in MeCN (3 ml) at 0 oC was 
added phosphorus trichloride (60 µl, 0.68 mmol) and then triethylamine (334 µl, 2.4 
mmol). After 15 min, a solution of compound 33 (200 mg, 0.16 mmol) in MeCN (3 
ml) was added dropwise during 15 min at 0 oC. The mixture was stirred for 30 min at 
rt and the reaction was quenched with 1M TEAB buffer solution (2-3 ml). The 
reaction mixture was diluted with CH2Cl2 (40 ml), washed successively with ice-water 
and cold 0.5M TEAB solution, dried by filtration through cotton wool and 
concentrated. FFC [CH2Cl2-methanol (9:1)] of the residue gave the derivative 34-α,β 
(218 mg, 0.152 mmol, 95 %; an anomeric mixture at D-mannose residue) with a α/β 
ratio of 12:1 (determined using 1H and 31P NMR data). 
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The prepared compound 34-α,β was dissolved in a mixture of CH2Cl2 (4.2 ml) and 
methanol (0.9 ml). To this a solution of silver triflate (105 mg, 0.405 mmol) in 
toluene (2 ml) was added dropwise. After 40 min, the reaction was quenched by 
addtion of cold 1M TEAB buffer solution. The mixture was diluted with CH2Cl2, 
washed with cold 0.5M TEAB buffer solution, dried by filtration through cotton wool 
and concentrated. The residue was filtered through a silica pad (to remove AgOTf) 
and concentrated. FFC [CH2Cl2-methanol (9:1)] of the residue gave the 
hydrogenphosphonate derivative 34 (106 mg, 0.076 mmol, 48 %; a pure α-anomer at 
D-mannose residue) as an amorphous solid. 
Method B 
The hemiacetal 33 (82.5 mg, 0.065 mmol) was dissolved in MeCN (2 ml), and to this 
solution triethylamine (600 µl, 4.24 mmol) and salicyl chlorophosphite (89 mg, 0.437 
mmol) were added under stirring. Monitoring by TLC (Solvent H) showed complete 
conversion of 33 to the H-phosphonate 34 after 1 h. The reaction mixture was 
diluted with CHCl3, and washed successively by saturated aq. NaHCO3, water and 
cold 0.5M TEAB buffer solution, dried by filtration through cotton wool and 
concentrated. FFC [CH2Cl2-methanol (9:1)] of the residue gave the 
hydrogenphosphonate derivative 34 (92 mg, 0.064 mmol, 98 %; a pure α-anomer at 
D-mannose residue) as an amorphous solid. 
[ ]20Dα +32.4 (c 1, CHCl3). 
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1H NMR (CDCl3): δH 1.30 (9H, t, 3 x MeCH2), 3.09 (7H, m, H-6a’ & MeCH2), 3.24, (1H, 
dd, J5’,6b’ 5.0, J6a’,6b’ 8.6, H-6b’), 3.65, 3.66 (6H, 2 x s, 2 x MeO), 3.77 (1H, br dd, J5’,6a’ 
9.3, H-5’), 4.31 (1H, dt, J5,6 2.8, H-5), 4.48 (1H, t, J3,4 = J4,5 = 9.8, H-4), 4.56 (2H, d, H-6a 
& H-6b), 4.89 (1H, d, J1’,2’ 7.9, H-1’), 5.47 (1H, dd, J3’,4’ 3.3, H-3’), 5.59 (1H, dd, J2’,3’ 
10.5, H-2’), 5.68 (1H, dd, J2,3 3.3, H-2), 5.72 (1H, dd, J1,2 2.0, J1,P 9.0, H-1), 5.76 (1H, dd, 
H-3), 5.98 (1H, br d, H-4’), 7.02 (1H, d, JH,P 636.1, HP) and 6.53-8.05 (43H, m, C6H4 & 
Ph). 
13C NMR (CDCl3): δc 8.47 (MeCH2), 45.55 (MeCH2), 55.05 (OMe), 59.55 (C-6’), 62.58 
(C-6), 67.39 (C-4’), 69.83 (C-3), 70.05 (C-5), 70.26 (C-2’), 70.86 (d, JC,P 6.9, C-2), 71.99 
(C-3’), 72.40 (C-5’), 72.78 (C-4), 86.27 (Ar3C), 92.60 (d, JC,P 3.6, C-1), 100.98 (C-1’), 
113.00, 126.72-130.30, 132.65-135.60 144.02, 158.28, 158.38 (C6H4 & Ph) and 
164.97-166.24 (C=0) 
31P NMR (CDCl3): δP 0.38. 
High resolution ES-MS(-): found m/z 1331.3780 [M - Et3N - H]
- (C81H80NO21P requires 
M: 1433.5012; C75H64O21P
- requires m/z 1331.3683). 
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2,3,6-Tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-butyldimethylsilyl-β-D-
galactopyranosyl)-α-D-mannopyranose 35 
 
Acetic acid (37 µl, 0.277 mmol) was added dropwise to a stirring solution of 
ethylenediamine (37 µl, 0.555 mmol) in THF (2 ml). This instantly formed a white 
precipitate. The protected disaccharide 30 (300 mg, 0.277 mmol) was added and the 
reaction mixture was left for 20 h under stirring. TLC (Sovlent G) showed the reaction 
was complete. Water was added and, after 10 min, the reaction mixture was diluted 
with CH2Cl2 and washed successively with 1M HCl, water and saturated aq. NaHCO3, 
dried (MgSO4) and concentrated. FCC [toluene-ethyl acetate (85:15)] of the residue 
yielded the hemiacetal derivative 35 (282 mg, 0.241 mmol, 87 %) as an amorphous 
solid. 
1H NMR (CDCl3): δH -0.08 (3H, s, CH3Si), 0.00 (3H, s, CH3Si), 0.92 (9H, s, tert-Bu), 3.41-
3.49 (2H, m, H-6b’ & H-6a’), 3.73 (1H, ddd, J5’,6a’ 5.7, J5’,6b’ 8.8, H-5’), 4.58 (1H, ddd, 
J5,6a 2.9, H-5), 4.67 (1H, dd, J6a,6b 12.2, H-6a), 4.75 (1H, t, J3,4 = J4,5 =  9.6, H-4),  4.96 
(1H, dd, J5,6b 1.9, H-6b), 5.18 (1H, d, J1’,2’ 7.9 H-1’), 5.57 (1H, br, H-1) 5.69 (1H, dd, J2’,3’ 
10.5, J3’,4’ 3.4, H-3’), 5.88-5.93 (2H, m, H-2 & H-2’), 5.96 (1H, dd, J4’,5’ 0.8, H-4’), 6.22 
(1H, dd, J2,3 3.4, H-3) and 7.36-8.25 (30H, m, Ph). 
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13C NMR (CDCl3): δc  -5.94, -5.79 (CH3Si), 18.01 (Me3C), 25.63, (Me3C), 59.35 (C-6’), 
62.21 (C-6), 67.06 (C-4’), 69.34 (C-5), 70.46 (C-2’ & C-3), 70.73 (C-2), 71.86 (C-3’), 
73.45 (C-4), 73.82 (C-5’), 92.22 (C-1), 101.49 (C-1’), 128.19-133.31 (Ph) and 164.06-
166.67 (C=O). 
High resolution ES-MS(+): found m/z 1103.3498 [M + Na]+ (C60H60O17Si requires M: 
1080.3600; C60H60NaO17Si requires m/z 1103.3492). 
 
 
2,3,6-Tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-butyldimethylsilyl-β-D-
galactopyranosyl)-α-D-mannopyranosyl hydrogenphosphonate, 
triethylammonium salt 36 
 
Compound 35 (70 mg, 0.065 mmol) was dissolved in MeCN (2 ml), and to this 
solution triethylamine (600 µl, 4.24 mmol) and salicyl chlorophosphite (89 mg, 0.437 
mmol) were added under stirring. Monitoring by TLC (Solvent H) showed complete 
conversion of 35 after 1 h. The reaction mixture was diluted with CHCl3, and washed 
successively by saturated aq. NaHCO3, water and cold 0.5M TEAB buffer solution, 
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dried by filtration through cotton wool and concentrated. FFC [CH2Cl2-methanol 
(9:1)] of the residue gave the hydrogenphosphonate derivative 36 (79 mg, 0.0634 
mmol, 98 %; a pure α-anomer at D-mannose residue) as an amorphous solid. 
1H NMR (CDCl3): δH -0.07 (3H, s, CH3Si), 0.00 (3H, s, CH3Si), 0.92 (9H, s, tert-Bu), 1.58 
(9H, t, 3 x MeCH2), 3.28 – 3.34 (6H, m, 3 x MeCH2), 3.41-3.49 (2H, m, H-6a’ & 6b’), 
3.74 (1H, dd, J5’,6a’ 5.9, J5’,6b’ 8.1, H-5’), 4.61 (1H, br d, H-5), 4.72 (1H, t, J3,4 = J4,5 = 9.5, 
H-4), 4.73 (1H, m, H-6a), 4.84 (1H, br d, J6a,6b 12.2, H-6b), 5.15 (1H, d, J1’,2’ 7.9, H-1’), 
5.66 (1H, dd, J3’,4’ 3.3, H-3’), 5.87 (1H, dd, J2’,3’ 10.3, H-2’), 5.92-5.98 (3H, m, H-1, H-2 
& H-4’), 6.14 (1H, dd, J2,3 3.2, H-3), 7.25 (1H, d, JH,P 638.4, HP) and 7.30-8.30 (30H, m, 
Ph).  
13C NMR (CDCl3): δc -5.80 (CH3Si), 8.57 (MeCH2), 45.68 (MeCH2), 18.01 (Me3C), 25.63, 
(Me3C), 59.45 (C-6’), 62.53 (C-6), 67.14 (C-4’), 70.24 (C-5), 70.37 (C-2’), 70.71 (C-3), 
70.91 (br, C-2), 71.94 (C-3’), 73.41 (C-4), 73.51 (C-5’), 92.85 (br, C-1), 101.30 (C-1’), 
128.12-133.15 (Ph) and 164.06-166.67 (C=O). 
31P NMR (CDCl3): δp 0.50. 
ES-MS(+): found m/z 1246.4578 [M + H]+ (C66H76NO19PSi requires M: 1245.4518; 
C66H77NO19PSi
+ requires m/z 1246.4572). 
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Methyl 2,3,6-tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-6-O-tert-
butyldimethylsilyl-β-D-galactopyranosyl)-α-D-mannopyranoside 37 
 
A mixture of compounds 24 (750 mg, 0.999 mmol) and 25 (496 mg, 0.832 mmol g) 
was dissolved in freshly distilled CH2Cl2 (4 ml), before freshly activated molecular 
sieves 4Å (500 mg) were added. This suspension was cooled to -40 oC under stirring 
and trimethylsilyl trifluoromethanesulfonate (18 µl, 0.1 mmol) was injected through 
the septa. Monitoring by TLC (Solvent A) showed that after 90 minutes the glycosyl 
donor 24 was consumed. The reaction was quenched by the addition of 
triethylamine (500 µl) and left for 10 min. The mixture was diluted with CH2Cl2, 
filtered through a Celite pad to remove solids and the filtrate was concentrated. FCC 
[toluene-ethyl acetate (100:0→95:5)] of the residue gave the protected disaccharide 
37 (676 mg, 0.570 mmol, 68 %) as an amorphous sold. 
[ ]20Dα +25.3 (c 1, CHCl3). 
1H NMR (CDCl3): δH -0.09 (3H, s, CH3Si), 0.00 (3H, s, CH3Si), 0.92 (9H, s, tert-Bu), 3.43 
(2H, d, J5’,6’ 7.2, H-6a’ & H-6b’), 3.66 (3H, s, OMe), 3.73 (1H, br t, H-5’), 4.34 (1H, ddd, 
J5,6a 3.4, H-5), 4.69 (1H, dd, J6a,6b 11.9, H-6a), 4.72 (1H, t, J3,4 = J4,5 = 9.6, H-4), 4.92 
(1H, dd, J5,6b 1.6, H-6b), 5.07 (1H, d, J1,2 1.8 H-1), 5.16 (1H, d, J1’,2’ 7.9, H-1’), 5.68 (1H, 
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dd, J2’,3’ 10.4, H-3’), 5.86 (1H, dd, J2,3 3.4, H-2), 5.90 (1H, dd, H-2’), 5.96 (1H, br d, J3’,4’ 
3.3, H-4’), 5.79 (1H, dd, H-3) and 7.35-8.31 (30H, m, Ph). 
13C NMR (CDCl3): δc -5.94, -5.80 (CH3Si), 18.01 (Me3C), 25.81 (Me3C), 55.39 (OMe), 
59.29 (C-6’), 62.33 (C-6), 67.00 (C-4’), 69.17 (C-5), 70.33 (C-2), 70.41 (C-2’), 70.73 (C-
3), 71.89 (C-3’), 73.42 (C-5’), 73.88 (C-4), 98.49 (C-1), 101.47 (C-1’), 128.34–133.51 
(Ph) and 164.06-166.67 (C=O). 
 
 
Methyl 2,3,6-tri-O-benzoyl-4-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-
α-D-mannopyranoside 38 
 
Acetonitrile (1 ml) was used to dissolve the disaccharide 37 (100 mg, 0.091 mmol), 
and the solution was cooled to 0 oC. A mixture of 40 % aq. HF and MeCN (1:1, 1 ml) 
was added under stirring. The reaction was run for 1 h and monitored by TLC 
(Solvent E). To stop the reaction saturated aq. NaHCO3 was added dropwise to the 
mixture until the bubbling stopped. The reaction mixture was diluted with CH2Cl2, 
washed with water (5 x 40 ml), dried (MgSO4) and concentrated. FCC [toluene-ethyl 
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acetate (98:2→80:20)] of the residue yielded 38 (80 mg, 0.09 mmol, 98 %) as an 
amorphous solid. 
1H NMR (CDCl3): δH 2.96 (1H, dd, J6a’,6b’ 12.1, H-6a’), 3.06 (1H, dd, J5’,6b’ 6.4, H-6b’), 
3.36 (3H, s, OMe), 3.49 (1H, br dd, J5’,6a’ 7.1, H-5’), 4.05 (1H, ddd, J5,6a 3.5, H-5), 4.42 
(1H, dd, J6a,6b 12.2, H-6a), 4.45 (1H, t, J3,4 = J4,5 = 9.6, H-4), 4.62 (1H, dd, J5,6b 1.9, H-
6b), 4.79 (1H, d, J1,2 1.9 H-1), 4.87 (1H, d, J1’,2’ 7.9, H-1’), 5.33 (1H, dd, J2’,3’ 10.4, H-3’), 
5.51 (1H, br d, J3’,4’ 3.4, H-4’), 5.53 (1H, dd, J2,3 3.4, H-2), 5.71 (1H, dd, H-2’), 5.79 (1H, 
dd, H-3) and 7.06-8.11 (30H, m, Ph). 
13C NMR (CDCl3): δc 55.42 (OMe), 59.90 (C-6’), 62.42 (C-6), 68.51 (C-4’), 69.20 (C-5), 
70.21 (C-2 & C-2’), 70.59 (C-3), 71.77 (C-3’), 73.82 (C-5’), 74.00 (C-4), 98.49 (C-1), 
101.21 (C-1’), 128.34-133.51 (Ph) and 164.06-166.67 (C=O). 
High resolution ES-MS(+): found m/z 1003.2761 [M + Na]+ (C55H48O17 requires M: 
980.2892; C55H48NaO17
+ requires m/z 1003.2784). 
 
 
 
 
132 
 
1,2,3,6-Tetra-O-benzoyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-α-
D-mannopyranose 39 
 
A mixture of compounds 29 (300 mg, 0.609 mmol) and 21 (330 mg, 0.553 mg) was 
dissolved in freshly distilled CH2Cl2 (5 ml), before freshly activated molecular sieves 
4Å (500 mg) were added. This suspension was cooled to -40 oC under stirring and 
trimethylsilyl trifluoromethanesulfonate (39 µl, 0.216 mmol) was injected through 
the septa. Monitoring by TLC (Solvent D) showed that after 30 minutes the glycosyl 
donor 29 was consumed. The reaction was quenched by the addition of a mixture of 
methanol (10 µl), triethylamine (10 µl) and CH2Cl2 (1 ml) and left for 10 min. The 
mixture was diluted with CH2Cl2, filtered through a Celite pad to remove solids and 
the filtrate was concentrated. FCC [toluene- ethyl acetate (100:0→95:5)] of the 
residue gave the disaccharide 39 (496 mg, 0.536 mmol, 88 %) as an a amorphous 
solid. 
[ ]20Dα +14.1 (c 1, CHCl3). 
1H NMR (CDCl3): δH 1.69, 1.85, 1.92, 1.94 (12H, 4 x s, 4 x Ac), 3.37 (1H, br dd, J5’,6a’ 5.8, 
H-5’), 3.42 (1H, dd, J6a’,6b’ 10.8, H-6’), 3.67 (1H, dd, J5’,6b’ 7.8, H-6b), 4.25 (1H, ddd, J5,6a 
3.3, H-5), 4.44 (1H, dd, J6a,6b 12.2, H-6a), 4.53 (1H, t, J3,4 =  J4,5 = 9.6, H-4), 4.65 (1H, d, 
J1’,2’ 8.0, H-1’), 4.71 (1H, dd, J5,6b 2.0, H-6b), 4.80 (1H, dd, J3’,4’ 3.4, H-3’), 5.09 (2H, m, 
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H-2’ & H-4’), 5.78 (1H, dd, J2,3 3.4, H-2), 5.87 (1H, dd, H-3), 6.45 (1H, d, J1,2 2.1, H-1) 
and 7.05-8.11 (20H, m, Ph).  
13C NMR (CDCl3): δc 20.32, 20.53, 20.70 (MeCO), 60.28 (C-6’), 62.18 (C-6), 66.37 (C-
4’), 69.26 (C-2’), 69.32 (C-2), 70.33 (C-3), 70.65 (C-5’), 70.96 (C-3’), 71.54 (C-5), 73.45 
(C-4), 91.27 (C-1), 101.20 (C-1’), 128.25-134.11 (Ph), 164.02, 164.94, 165.84 (PhCO2) 
and 169.36, 169.88, 170.10 (MeCO2). 
High resolution ES-MS(+): found m/z 949.2572 [M + Na]+ (C48H46O19 requires M: 
926.2633; C48H46NaO19
+ requires m/z 949.2526). 
 
 
2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl hydrogenphosphonate, 
triethylammonium salt 40 
 
To a stirred solution of imidazole (486 mg, 7.20 mmol) in MeCN (12 ml) at 0 oC was 
added phosphorus trichloride (189 µl, 2.16 mmol) and then triethylamine (1.05 ml, 
7.54 mmol). After 15 min, a solution of compound 53 (2,3,4,6-tetra-O-benzoyl-α-D-
glucopyranose) (300 mg, 0.5 mmol) in MeCN (7 ml) was added dropwise during 15 
mins at 0 oC.  After 30 min at rt, the reaction was quenched with cold 1M TEAB 
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buffer solution (3 ml). After a further 15 min, the mixture was diluted with CH2Cl2 (40 
ml) and washed successively with ice-water (twice) and cold 0.5M TEAB solution 
(twice), dried by filtration through cotton wool and concentrated. FFC [CH2Cl2-
methanol (95:5)] of the residue gave the H-phosphonate derivative 40 (282 mg, 0.39 
mmol, 78 %) as an amorphous solid. 
[ ]20Dα +65.7 (c 1, CHCl3). 
1H NMR (CDCl3): δH 1.10 (9H, t, 3 x MeCH2), 3.27 (6H, m, 3 x MeCH2), 4.36 (1H, dd, 
J6a,6b 12.3, H-6a), 4.55 (1H, dd, J5,6b 2.9, H-6b), 4.73 (1H, ddd, J5,6a 4.3, H-5), 5.32 (1H, 
ddd, 4J2,P 1.2, H-2), 5.69 (1H, t, J3,4 = J4,5 = 9.9, H-4), 6.01 (1H, dd, J1,2 3.4, J1,P 8.8, H-1), 
6.22 (1H, t, J2,3 9.9,  H-3), 6.99 (1H, d, 
1
JH,P 638, HP) and 7.17-8.00 (20H, m, Ph). 
13C NMR (CDCl3): δc 8.55 (MeCH2), 45.52 (MeCH2), 62.78 (C-6), 68.71 (C-5), 69.37 (C-
4), 70.48 (C-3), 71.83 (d, 3JC,P 5.7, C-2), 91.60 (d, 
2
JC,P 4.2, C-1), 128.26-133.82 (Ph) and 
165.25-165.71 (C=O). 
31P NMR (CDCl3): δp 0.82. 
High resolution ES-MS(-):  found m/z 659.1315 [M - Et3N - H]
- (C40H44NO12P
- requires 
M, 761.2601, C34H28O12P
- requires m/z 659.1324). 
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6-N-Biotinylaminohexyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl 
phosphate, triethylammonium salt 41 
 
A mixture of compounds 40 (200 mg, 0.26 mmol) and 27 (82 mg, 0.23 mmol) was 
dried by evaporation of pyridine (3 x 5 ml) therefrom. The residue was dissolved in 
pyridine (2 ml), pivaloyl chloride (96 µl, 0.78 mmol) was added and the mixture was 
left to stir at rt for 90 min, whereafter TLC (Solvent A) showed formation of a new 
spot. A freshly prepared solution of iodine (230 mg, 0.91 mmol) in pyridine-water 
(95:5, 1 ml) was added. After 30 min, the mixture was diluted with CH2Cl2 and 
washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer and water, 
dried by filtration through cotton wool and concentrated. FCC [CH2Cl2-methanol 
(100:0→95:5)] of the residue gave the phosphodiester 41 (190 mg, 0.177 mmol, 77 
%) as an amorphous solid. 
1H NMR (CDCl3): δH 1.16 (9H, t, 3 x MeCH2), 1.25-1.63 (14H, m, 7 x CH2), 2.13 (2H, t, J 
7.4, CH2CO), 2.66 (1H, br d, Ja,b 12.8, H
b), 2.87 (1H, dd, Ja,c 4.9, H
a), 2.87 (6H, q, 3 x 
MeCH2), 3.02-3.07 (1H, m, H
e), 3.09-3.17 (2H, q, J 6.1, CH2N), 3.72-3.85 (2H, m, 
CH2OP), 4.23 (1H, m, H
d), 4.33 (1H, dd, J6a,6b 12.3, H-6a), 4.40 (1H, m, H
c), 4.63 (1H, 
dd, J5,6b 2.8, H-6b), 4.73 (1H, ddd, J5,6a 5.8, H-5), 5.10 (1H, br, NH), 5.24 (1H, ddd, 
4
J2,P 
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1.7, H-2), 5.74 (1H, t, J3,4 = J4,5 = 9.9, H-4), 5.96  (1H, dd, J1,2 3.3, J1,P 7.8, H-1), 6.05 
(1H, br, NH), 6.22 (1H, t, J2,3 9.9,  H-3), 7.75 (1H, m, CH2NH) and 7.18-8.02 (20H, m, 
Ph). 
13C NMR (CDCl3): δc 8.51 (MeCH2), 24.86, 25.75, 25.98, 28.08, 29.16, 29.71 (6 x CH2), 
30.16 (d, 3JC,P 8.1, CH2CH2OP), 35.80 (CH2CO), 38.98 (CH2N), 40.55 (C
ab), 45.70 
(MeCH2), 55.62 (C
e), 60.25 (Cc), 61.95 (Cd), 62.61 (C-6), 65.61 (br, CH2OP) 68.50 (C-5), 
69.20 (C-4), 70.42 (C-3), 72.11 (d, 3JC,P 8.0, C-2), 92.24 (br, C-1), 128.32-133.42 (Ph), 
165.23, 165.75, 166.24 (PhC=O) and 173.37 (CH2CONH). 
31P NMR (CDCl3): δp -2.18. 
High resolution ES-MS(-): found m/z  1000.3125 [M - Et3N - H]
- (C56H71N4O15PS 
requires M: 1102.4374; C50H55N3O15SP
- requires m/z 1000.3097). 
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6-N-Biotinylaminohexyl 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-
(p,p’-dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranosyl 
phosphate, triethylammonium salt 42 
 
A mixture of compounds 34 (80 mg, 0.056 mmol) and 27 (20 mg, 0.056 mmol) was 
dried by evaporation of pyridine (3 x 5 ml) therefrom. The residue was dissolved in 
pyridine (1 ml), pivaloyl chloride (21 µl, 0.167 mmol) was added and the mixture was 
left to stir at rt for 90 min, whereafter TLC (Solvent A) showed formation of a new 
spot. A freshly prepared solution of iodine (42 mg, 0.112 mmol) in pyridine-water 
(95:5, 1 ml) was added. After 30 min, the mixture was diluted with CH2Cl2 and 
washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer and water, 
dried by filtration through cotton wool and concentrated. TLC (Solvent H) showed a 
very faint spot, which was thought to be the product. FCC [CH2Cl2-methanol 
(100:0→95:5)] of the residue gave the biotin linked disaccharide phosphate 42 (8 
mg, 0.0045 mmol, 8%) as an amorphous solid. 
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1H NMR (CD3OD): δH 1.15-1.50 (m, 3 x MeCH2 & 7 x CH2), 2.24 (m, CH2CO), 2.90-3.25 
(m, 3 x MeCH2, H-6a’, H-6b’, H
a, Hb, He & CH2NH), 3.52 (m, CH2OP), 3.56, 3.57, 3.58, 
3.59 (4 x s, 2 x OMe, signals duplicated due to possible rotamers), 3.65 (m, H-5’), 
4.05 (m, Hd), 4.23 (m, H-5 & Hc), 4.35-4.56 (m, H-4, H-6a & H-6b), 4.80, 4.84 (2 x d, 
J1’,2’ 7.9, H-1’, signals duplicated due to possible rotamers), 5.38 (m, H-3’), 5.47-5.62 
(m, H-1, H-2, & H-2’), 5.64, 5.72 (2 x dd, J2,3 3.2, J3,4 9.7, H-3, signals duplicated due to 
possible rotamers), 5.87 (d, J3’,4’ 3.3, H-4’) and 6.45-7.92 (m, 7 x Ph & 2 x C6H4). 
31P NMR (CDCl3): δp -2.18. 
 
 
Attempted coupling of 2,3,6-tri-O-benzoyl-4-O-[2,3,4-tri-O-benzoyl-6-O-
(p,p’-dimethoxytrityl)-β-D-galactopyranosyl]-α-D-mannopyranosyl 
hydrogenphosphonate 34 and the Gal-linker-Fmoc derivative 43 
 
A mixture of compounds 34 (80 mg, 0.056 mmol) and 43 (63 mg, 0.077 mmol) was 
dried by evaporation of pyridine (3 x 4 ml) therefrom. The residue was dissolved in 
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pyridine (1.5 ml), pivaloyl chloride (26 µl, 0.21 mmol) was added and the mixture 
was left to stir at rt for 2 h, whereafter a freshly prepared solution of iodine (36 mg, 
0.140 mmol) in pyridine-water (95:5, 1 ml) was added. After 30 min, the mixture was 
diluted with CH2Cl2 and washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M 
TEAB buffer and water, dried by filtration through cotton wool and concentrated. It 
could be seen by TLC (Solvent H) that no expected phosphodiester product was 
formed. 
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Methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-
α-D-mannopyranoside 6-(6-N-biotinylaminohexyl phosphate), 
triethylammonium salt 44 
                                          
 
A mixture of the H-phosphonate 28 (101.4 mg, 0.249 mmol) and the disaccharide 38 
(122 mg, 0.124 mmol) was dried by evaporation of pyridine (3 x 5 ml) therefrom. The 
residue was dissolved in pyridine (2 ml) and triethylamine (70 µl, 0.498 mmol) was 
added. Pivaloyl chloride (107 µl, 0.868 mmol) was then added and the mixture was 
left to stir at rt for 60 min, whereafter TLC (Solvent A) showed that the disaccharide 
38 was consumed. A freshly prepared solution of iodine (126.3 mg, 0.498 mmol) in 
pyridine-water (95:5, 1 ml) was added. After 20 min, the mixture was diluted with 
CH2Cl2 and washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer 
and water, dried by filtration through cotton wool and concentrated. TLC (Solvent H) 
showed a strong new spot, which was thought to be the product.  
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FCC [CH2Cl2-methanol (90:10→80:20)] of the residue gave the protected biotin 
linked disaccharide phosphate 44 (165 mg, 0.104 mmol, 84%) as an amorphous solid. 
1H NMR (CDCl3): δH 1.16-1.72 (23H, m, 3 x MeCH2 & 7 x CH2), 2.10 (2H, m, CH2CO), 
2.64 (1H, br d, Ja,b 12.5, H
b), 2.92 (1H, dd, Ja,c 5.0, H
a), 2.94 (6H, q, 3 x MeCH2), 3.01 
(1H, m, He), 3.08 (2H, m, CH2N), 3.31 (1H, m, H-6a’), 3.35 (3H, s, OMe), 3.49-3.62 (2H, 
m, CH2OP), 3.78 (1H, m, H-6b’), 3.99 (1H, dt, J5,6 2.9, H-5), 4.04 (1H, m, H-5’), 4.17 
(1H, m, Hd), 4.33 (1H, m, Hc), 4.43 (1H, t, J3,4 = J4,5 = 9.7, H-4), 4.53 (2H, d, J5,6 2.9, H-
6a & H-6b), 4.79 (1H, d, J1,2 1.5 H-1), 4.92 (1H, d, J1’,2’ 7.9, H-1’), 5.34 (1H, dd, J3’,4’ 3.3, 
H-3’), 5.53 (1H, dd, J2,3 3.4, H-2), 5.58 (1H, dd, J2’,3’ 10.3, H-2’), 5.74 (2H, m, H-3 & H-
4’), 6.38 (1H, br, NH) 6.71 (1H, br, NH) and 7.06-8.00 (31H, m, CH2NH & Ph). 
13C NMR (CDCl3): δc 8.50 (MeCH2), 24.78, 25.77, 27.96, 28.88, 29.70 (6 x CH2), 30.02 
(br, CH2CH2OP), 35.80 (CH2CO), 38.95 (CH2N), 40.61 (C
ab), 45.45 (MeCH2), 55.39 
(OMe), 55.68 (Ce), 60.07 (Cc), 61.39 (br, C-6’), 62.00 (Cd), 62.76 (C-6), 64.97 (br, 
CH2OP), 67.29 (C-4’), 69.61 (C-5), 69.70 (C-3), 70.18 (C-2’), 70.76 (C-2), 70.91 (br, C-
5’), 72.49 (C-3’), 73.51 (C-4), 98.41 (C-1), 101.07 (C-1’), 128.25-133.21 (Ph), 165.25, 
165.42, 165.60 (PhC=O) and 173.38 (CH2CONH). 
31P NMR (CDCl3): δp -0.47. 
High resolution ES-MS(+): found m/z 1386.4489 [M - Et3N + H]
+ (C77H91N4O22PS 
requires M: 1486.5583; C71H77N3O22PS
+ requires m/z 1386.4452) and 1408.4313 [M - 
Et3N + Na]
+ (C71H76N3NaO22PS
+ requires m/z 1408.4276). 
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Methyl 2,3,4-tri-O-benzoyl-6-O-tert-butyldimethylsilyl-β-D-galactopyranosyl-
(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranoside 6-[2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl 
phosphate] triethylammonium salt 45 
 
 
A mixture of compounds 36 (65 mg, 0.052 mmol) and 38 (42.7 mg, 0.044 mmol) was 
dried by evaporation of pyridine (3 x 5 ml) therefrom. The residue was dissolved in 
pyridine (2 ml), pivaloyl chloride (31 µl, 0.25 mmol) was added and the mixture was 
left to stir at rt for 90 min, whereafter TLC (Solvent A) showed that the H-
phosphonate 36 was consumed. A freshly prepared solution of iodine (32.1 mg, 
0.125 mmol) in pyridine-water (95:5, 1 ml) was added. After 1 h, the mixture was 
diluted with CH2Cl2 and washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M 
TEAB buffer and water, dried by filtration through cotton wool and concentrated. 
FCC [CH2Cl2-methanol (95:5→90:10)] of the residue gave the protected 
tetrasaccharide phosphate 45 (80 mg, 0.036 mmol, 82 %) as a amorphous solid. 
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1H NMR (CDCl3): δH : -0.08 (3H, s, CH3Si), 0.00 (3H, s, CH3Si), 0.94 (9H, s, tert-Bu), 1.58 
(9H, t, 3 x MeCH2), 3.27 (6H, m, 3 x MeCH2), 3.39-3.49 (3H, m, H-6a Gal , H-6a & H-6b 
Gal’), 3.67 (3H, s, OMe), 3.69 (1H, m, H-5 Gal’), 4.14-4.20(1H, m, H-6b Gal), 4.29 (1H, 
ddd, J4,5 9.7, J5,6a 2.1, J5,6b 4.1, H-5 Man’), 4.40 (1H, dd, J5,6a 9.3, J5,6b 5.6, H-5 Gal), 
4.48-4.88 (7H, m, H-4, H-5, H-6a H-6b Man & H-4, , H-6a, H-6b Man’), 5.12 (1H, d, J1,2 
1.8, H-1 Man), 5.13 (1H, d, J1,2 7.8, H-1 Gal’), 5.23 (1H, d, J1,2 7.8, H-1 Gal), 5.65 (2H, 
dd, J2,3 10.4, J3,4 3.3, H-3 Gal & H-3 Gal’), 5.71 (1H, dd, J1,2 1.9, J1,P 7.0, H-1 Man’), 5.81 
(1H, dd, J2,3 3.5, H-2 Man), 5.86-5.97 (4H, m , H-2 Gal, H-2 Man’ & H-2, H-4 Gal’), 
6.07-6.12 (3H, m, H-3 Man, H-3 Man’ & H-4 Gal) and 7.35-8.32 (60H, m, Ph). 
13C NMR (CDCl3): δc -5.94, -5.82 (CH3Si), 8.65 (MeCH2), 17.86 (Me3C), 25.61 (Me3C), 
45.71 (MeCH2), 55.35 (OMe), 59.35 (C-6 Gal’), 61.46 (br, C-6 Gal), 62.17 (C-6 Man), 
62.49 (C-6 Man’), 67.03 (C-4 Gal’), 67.15 (C-4 Gal), 69.23 (C-3 Man), 69.78 (C-5 Man’), 
69.86 (C-5 Man’), 70.39 (C-2 Gal), 70.43 (C-2 Gal’), 70.52 (d, JC,P 7.5, C-2 Man’), 70.62 
(C-3 Man’), 71.02 (C-2 Man), 72.07 (d, JC,P 5.6, C-5 Gal & C-3 Gal’), 72.58 (C-3 Gal), 
73.16 (C-4 Man’), 73.32 (C-5 Gal’), 74.03 (C-4 Man), 93.57 (br, C-1 Man’) 98.41 (C-1 
Man), 101.15 (C-1 Gal’), 101.36 (C-1 Gal), 127.98-133.45 (Ph) and 164.32-165.55 
(C=O). 
31P NMR (CDCl3): δp -4.34. 
High resolution ES-MS(-): found 2121.5985 m/z [M - Et3N - H]
- (C121H122NO36PSi 
requires M: 2223.7253; C115H106O36PSi
- requires m/z 2121.5976). 
 
144 
 
Methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-
α-D-mannopyranoside 6-[2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate] triethylammonium salt 
46 
 
 
Compound 45 (250 mg, 0.112 mmol) was dissolved in MeCN (3 ml), and the solution 
was cooled to 0oC. A mixture of 40 % aq. HF and MeCN (1:1, 3 ml) was added under 
stirring. The reaction was run for 2 h, whereafter TLC (Solvent H) showed the 
deprotection was complete.  Saturated aq. NaHCO3 was added dropwise to the 
reaction mixture until the bubbling stopped. The mixture was then diluted with 
CHCl3, washed successively with saturated aq. NaHCO3, water, cold 0.5M TEAB 
buffer and water, dried by filtration through cotton wool and concentrated. FCC 
[CH2Cl2–methanol (100:0→98:2)] gave the tetrasaccharide phosphate 46 (212.7 mg, 
0.101 mmol, 90%) as a amorphous solid. 
1H NMR (CDCl3): δH 1.17 (9H, t, 3 x MeCH2), 2.91 (6H, m, 3 x MeCH2), 2.97 (1H, dd, 
J6a,6b 12.0  H-6a Gal’), 3.10 (1H, dd, H-6b Gal’), 3.16 (1H, m, H-6a Gal), 3.34 (3H, s, 
OMe), 3.45 (1H, t, , J5,6a = J5,6b = 6.5, H-5 Gal’), 3.85 (1H, m, H-6b Gal), 3.96 (1H, ddd, 
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J4,5 10.5, J5,6a 1.8, J5,6b 4.0, H-5 Man’), 4.08 (1H, dd, J5,6a 9.4, J5,6b 5.5, H-5 Gal), 4.26-
4.56 (7H, m, H-4, H-5, H-6a, H-6b Man & H-4, H-6a, H-6b Man’), 4.79 (1H, d, J1,2 1.6, 
H-1 Man), 4.82 (1H, d, J1,2 7.9, H-1 Gal’), 4.91 (1H, d, J1,2 7.9, H-1 Gal), 5.27 (1H, dd, 
J3,4 3.4, H-3 Gal’), 5.33 (1H, dd, J2,3 10.4, H-3 Gal), 5.39 (1H, dd, J1,2 1.8, J1,P 6.8, H-1 
Man’), 5.48 (2H, m, H-2 Man’ & H-4 Gal’), 5.61 (2H, m , H-2 Man & H-2 Gal), 5.67 (1H, 
dd, J2,3 10.4, H-2 Gal’), 5.75 (1H, dd, J2,3 3.5, J3,4 9.7, H-3 Man’), 5.77 (1H, d, J3,4 3.3, H-
4 Gal), 5.83(1H, dd, J2,3 3.4, J3,4 9.6, H-3 Man) and 7.05-7.96 (60H, m, Ph). 
13C NMR (CDCl3): δc 8.73 (MeCH2), 45.41 (MeCH2), 55.37 (OMe), 60.12 (C-6 Gal’), 
61.56 (d, JC,P 7.1, C-6 Gal), 62.33 (C-6 Man & C-6 Man’), 67.18 (C-4 Gal), 68.51 (C-4 
Gal’), 69.26 (C-3 Man’), 69.67 (C-5 Man & C-5 Man’), 69.87 (C-3 Man), 70.23 (C-2 
Gal), 70.34 (C-2 Gal’), 70.80 (br, C-2 Man’), 70.94 (C-2 Man), 71.96 (br, C-5 Gal & C-3 
Gal’), 72.53 (C-3 Gal), 73.73 (C-4 Man’), 74.00 (C-5 Gal’), 74.15 (C-4 Man), 93.51 (br, 
C-1 Man’) 98.40 (C-1 Man), 101.16 (C-1 Gal’), 101.37 (C-1 Gal), 128.29-133.27 (Ph) 
and 164.93-166.45 (C=O). 
31P NMR (CDCl3): δp -4.35. 
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Methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-
α-D-mannopyranoside 6-[2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 6-(6-N-
biotinylaminohexyl phosphate)], bistriethylammonium salt 47 
 
 
A mixture of the H-phosphonate 28 (46.2 mg, 0.113 mmol) and the tetrasaccharide 
phosphate 46 (192 mg, 0.091 mmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was dissolved in pyridine (1 ml), the solution was cooled to 0 
oC and triethylamine (31.9 µl, 0.227 mmol) was added. Pivaloyl chloride (47.1 µl, 
0.399 mmol) was then added and the mixture was left to stir at rt for 60 min, 
whereafter a freshly prepared solution of iodine (57 mg, 0.227 mmol) in pyridine-
water (95:5, 1 ml) was added. After 40 min, the mixture was diluted with CH2Cl2 and 
washed successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer and water, 
dried by filtration through cotton wool and concentrated. FCC [CH2Cl2-methanol 
(90:10→80:20)] of the residue gave the protected biotin linked tetrasaccharide 
diphosphate 47 (188 mg, 0.072 mmol, 79 %) as an amorphous solid. 
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1H NMR (CDCl3): δH 1.11-1.70 (32H, m, 7 x CH2 & 6 x MeCH2), 2.05-2.11 (2H, m, 
CH2CO), 2.61 (1H, d, Ja,b 12.7, H
b), 2.77 (1H, dd, Ja,c 5.0, H
a), 2.91 (12H, m, 6 x MeCH2), 
2.99 -3.10 (3H, m, He & CH2N), 3.14-3.25 (1H, m, H-6a Gal), 3.34 (3H, s, OMe), 3.35-
3.44 (1H, m, H-6a Gal’), 3.47-3.60 (2H, m, CH2OP), 3.74-3.80 (1H, m, H-6b Gal’), 3.84-
3.91 (2H, m, H-6b Gal & H-5 Gal’), 3.97 (1H, dt, J4,5 9.5, J5,6 2.9, H-5 Man’), 4.09 (1H, 
dd, J5,6a 9.0, J5,6b 5.6, H-5 Gal), 4.14-4.19 (1H, m, H-5 Man & H
d), 4.29-4.40 (3H, m, H-
6a, H-6b Man & Hc), 4.42-4.48 (2H, m, H-4 Man & H-4 Man’), 4.50-4.56 (2H, m, H-6a 
& H-6b Man’), 4.79 (1H, d, J1,2 1.6, H-1 Man), 4.89 (1H, d, J1,2 7.9, H-1 Gal’), 4.94 (1H, 
d, J1,2 7.9, H-1 Gal), 5.29 (1H, dd, J2,3 10.3, H-3 Gal’), 5.34 (1H, dd, J2,3 10.4, H-3 Gal), 
5.39 (1H, dd, J1,2 1.7, J1,P 7.1, H-1 Man’), 5.49 (1H, dd, J2,3 3.4, H-2 Man), 5.55-5.63 
(3H, m, H-2 Gal, H-2 Man’ & H-2 Gal’), 5.71 (1H, d, J3,4 3.2, H-4 Gal’), 5.74 (1H, dd, J2,3 
3.4, J3,4 10.3, H-3 Man’), 5.76 (1H, dd, J3,4 9.8, H-3 Man), 5.77 (1H, d, J3,4 3.3, H-4 Gal), 
5.88 (1H, br, NH) 6.43 (1H, br, NH) and 7.08-7.99 (61H, m, CH2NH & Ph). 
13C NMR (CDCl3): δc 8.56 (MeCH2), 24.83, 25.66, 25.75, 28.02, 28.93, 29.36 (6 x CH2), 
30.10 (br, CH2CH2OP), 35.82 (CH2CO), 38.89 (CH2N), 40.56 (C
ab), 45.51 (MeCH2), 55.33 
(OMe), 55.45 (Ce), 59.99 (Cc), 61.36 (br, C-6 Gal’), 61.56 (br, C-6 Gal), 61.94 (Cd), 
62.35 (C-6 Man), 62.55 (C-6 Man’), 67.25 (C-4 Gal), 67.31 (C-4 Gal’), 69.32 (C-3 Man), 
69.78 (C-3 Man’), 70.03 (C-5 Man’), 70.18 (C-5 Man & C-2 Gal’), 70.45 (C-2 Gal), 
70.74 (d, JC,P 6.5, C-2 Man’), 70.99 (C-2 Man), 72.02 (br, C-5 Gal & C-5 Gal’), 72.52 (C-
3 Gal & C-3 Gal’), 72.91 (C-4 Man’), 73.97 (C-4 Man), 93.52 (br, C-1 Man’), 98.40 (C-1 
Man), 100.96 (C-1 Gal’), 101.29 (C-1 Gal), 127.98-133.48 (Ph), 164.85-166.20 (PhC=O) 
and 173.18 (CH2CONH). 
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31P NMR (CDCl3): δp -4.43 (P), -0.64 (P’). 
High resolution ES-MS(-): found 1206.2823 m/z [M - 2Et3N - 2H]
2- (C137H151N5O41P2S 
requires M: 2615.9080; C125H119N3O41P2S
2- requires m/z 1205.8263) and 2412.5840 
m/z [M - 2Et3N - H]
- (C125H120N3O41P2S
- requires m/z 2412.6599). 
 
 
Methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-
α-D-mannopyranoside 6-{2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 6-[2,3,4-tri-O-benzoyl-
β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl 
phosphate]}, bistriethylammonium salt 48 
 
 
A mixture of the H-phosphonate 34 (53 mg, 0.037 mmol) and the tetrasaccharide 
phosphate 46 (65 mg, 0.0308 mmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was dissolved in pyridine (1 ml), pivaloyl chloride (16.4 µl, 
0.087 mmol) was added and the mixture was left to stir at rt for 2 h, whereafter a 
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freshly prepared solution of iodine (19 mg, 0.074 mmol) in pyridine-water (95:5, 1 
ml) was added. After 3 h, the mixture was diluted with CHCl3 and washed 
successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer and water, dried 
by filtration through cotton wool and concentrated. The residue was then dissolved 
in CH2Cl2 (5 ml) and 1 % TFA in CH2Cl2 (5 ml) was added at 0 
oC. After 2 min, the 
solution was washed successively with cold saturated aq. NaHCO3 and water, dried 
(MgSO4) and concentrated. FFC [CH2Cl2-methanol (90:10→85:15)] of the residue 
gave the hexasaccharide diphosphate 48 (68 mg, 0.019 mmol, 62%) as an 
amorphous solid. 
1H NMR (CDCl3): δH 1.11 (18H, t, 6 x MeCH2), 2.82 (12H, m, 3 x MeCH2), 2.95 (1H, dd, 
J5,6a 6.4,  J6a,6b 11.7  H-6a Gal”), 3.05-3.22 (3H, m, H-6a Gal, H-6a Gal’ & H-6b Gal”), 
3.33 (3H, s, OMe), 3.43 (1H, m, H-5 Gal”), 3.80 (1H, m, H-6b Gal’), 3.86 (1H, m, H-6b 
Gal), 3.90-3.98 (2H, m, H-5 Gal’ & H-5 Man”), 4.06 (1H, dd, , J5,6a 9.4,  J5,6b 5.0, H-5 
Gal), 4.14 (1H, br d, J4,5 9.4, H-5 Man’), 4.22-4.57 (10H, m, H-4, H-5, H6a, H6b Man, 
H-4, H-6a, H-6b Man’ & H-4, H-6a H-6b Man”), 4.79 (2H, m, H-1 Man & H-1 Gal’), 
4.83 (1H, d, J1,2 7.8, H-1 Gal”), 4.90 (1H, d, J1,2 7.7, H-1 Gal), 5.26 (2H, m, J2,3 10.1, H-3 
Gal’ & H-3 Gal”), 5.32 (2H, m, H-1 Man’ or Man” & H-3 Gal), 5.38 (1H, br d, J1,P 6.0, H-
1 Man’ or Man”), 5.48 (2H, m, H-2 Man” & H-4 Gal”), 5.53-5.69 (5H, m, H-2 Man, H-2 
Gal, H-2 Man’, H-2 Gal’, H-2 Gal”), 5.70-5.83 (5H, m, H-3 Man, H-4 Gal, H-3 Man’, H-4 
Gal’, H-3 Man”) and 7.03-7.96 (90H, m, Ph). 
13C NMR (CDCl3): δc 9.65 (MeCH2), 45.77 (MeCH2), 55.36 (OMe), 60.05 (C-6 Gal”), 
61.43k (2 x d, , JC,P 4.4, JC,P 6.5, C-6 Gal & C-6 Gal’), 62.17, 62.38, 62.45 (C-6 Man, C-6 
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Man’ & C-6 Man”), 67.09, 67.13 (C-4 Gal & C-4 Gal’), 68.47 (C-4 Gal”), 69.24 (C-3 
Man), 69.50 (C-3 Man”), 69.76 (C-3 Man’ & C-5 Man”), 69.84 (C-5 Man), 70.17 (C-5 
Man’), 70.22 (C-2 Gal’ & C-2 Gal”), 70.39 (C-2 Gal), 70.56 (d, JC,P 7.4, C-2 Man’), 70.81 
(d, JC,P 7.2, C-2 Man”), 70.96 (C-2 Man), 71.83 (d, JC,P 7.4, C-5 Gal’), 71.89 (C-3 Gal”), 
71.99 (d, JC,P 7.2, C-5 Gal), 72.51 (C-3 Gal & C-3 Gal’), 72.90 (C-4 Man’), 73.60 (C-4 
Man”), 73.96 (C-4 Man), 74.12 (C-5 Gal”), 93.43 (br, C-1 Man’ & C-1 Man”), 98.37 (C-
1 Man), 100.46 (C-1 Gal’), 101.35 (C-1 Gal & C-1 Gal”), 128.12-133.71 (Ph) and 
164.76-166.43 (C=O). 
31P NMR (CDCl3): δp -4.47, -4.38 (P & P’). 
High resolution ES-MS(-): found m/z 1517.8813 [M - 2Et3N - 2H]
2- (C175H168N2O55P2 
requires M: 3238.9886; C163H136O55P2
2- requires m/z 1517.3665) and 3035.8390 [M - 
2Et3N - H]
- (C163H137O55P2
- requires m/z 3035.7404). 
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Methyl 2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-
α-D-mannopyranoside 6-{2,3,4-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-α-D-mannopyranosyl phosphate 6-[2,3,4-tri-O-benzoyl-
β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-α-D-mannopyranosyl 
phosphate 6-(6-N-biotinylaminohexyl phosphate)]}, tristriethylammonium 
salt 49 
 
 
A mixture of the H-phosphonate 28 (11.3 mg, 0.0278 mmol) and the hexasaccharide 
diphosphate 48 (45 mg, 0.014 mmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was dissolved in pyridine (0.5 ml), the solution was cooled to 
0 oC and triethylamine (7.75 µl, 0.055 mmol) was added. Pivaloyl chloride (12.0 µl, 
0.097 mmol) was then added and the mixture was left to stir at rt for 2 h, whereafter 
a freshly prepared solution of iodine (14 mg, 0.055 mmol) in pyridine-water (95:5, 1 
ml) was added. After 3 h, the mixture was diluted with CH2Cl2 and washed 
successively with ice-cold 1M aq. Na2S2O3, cold 0.5M TEAB buffer and water, dried 
by filtration through cotton wool and concentrated. TLC (Solvent H) showed a strong 
spot; this was thought to be product. FCC [CH2Cl2–methanol (90:10→80:20)] of the 
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residue gave the protected biotin linked hexasaccharide triphosphate 49 (35 mg, 
0.009 mmol, 64 %) as an amorphous solid. 
1H NMR (CDCl3): δH 1.10-1.72 (41H, m, 7 x CH2 & 9 x MeCH2), 2.02-2.10 (2H, m, 
CH2CO), 2.64 (1H, d, Ja,b 12.3, H
b), 2.75 (1H, dd, Ja,c 4.9, H
a), 2.88 (18H, m, 9 x MeCH2), 
2.97-3.18 (5H, m, H-6a Gal, H-6a Gal’, He & CH2N), 3.33 (3H, s, OMe), 3.53-3.63 (3H, 
m, H-6a Gal” & CH2OP), 3.68-3.75 (1H, m, H-6b Gal’), 3.80-3.88 (3H, m, H-6b Gal, H-5 
Gal’ & H-5 Gal”), 3.91-4.03 (3H, m, H-5 Man’, H-5 Man” & H-6b Gal”), 4.07 (1H, dd, 
J5,6a 10.0, J5,6b 5.7, H-5 Gal), 4.12-4.56 (12H, m, H-4, H-5, H-6a, H-6b Man, H-4, H-6a, 
H-6b Man’, H-4, H-6a, H-6b Man”, Hc & Hd), 4.79 (1H, br, H-1 Man), 4.91 (3H, d, J1,2 
7.9, H-1 Gal, H-1 Gal’ & H-1 Gal”), 5.26-5.41 (5H, m, H-3 Gal, H-1 Man’, H-3 Gal’, H-1 
Man” & H-3 Gal”), 5.47 (1H, m, H-2 Man), 5.53-5.63 (5H, m, H-2 Gal, H-2 Man’, H-2 
Gal’, H-2 Man” & H-2 Gal”), 5.66 (1H, m, H-4 Gal”), 5.72-5.79 (5H, m, H-3 Man, H-4 
Gal, H-3 Man’, H-4 Gal’ & H-3 Man”), 6.53 (1H, br, NH), 7.03 (1H, br, NH) and 7.07-
7.95 (91H, m, CH2NH & Ph). 
13C NMR (CDCl3): δc 8.56 (MeCH2), 24.86, 25.72, 29.95, 27.52, 29.13, 29.50 (6 x CH2), 
30.23 (d, JC,P 9.3, CH2CH2OP), 35.72 (CH2CO), 38.73 (CH2N), 39.75(C
ab), 45.74 
(MeCH2), 55.33 (OMe & C
e), 60.43 (Cc), 62.03, 61.11, 62.14, 62.31 (C-6 Man, C-6 
Man’ C-6 Man” & Cd), 64.31, 64.36, 64.41, 64.48 (4 x br, C-6 Gal, C-6 Gal’, C-6 Gal” & 
CH2OP), 68.16, 68.87 (C-4 Gal, C-4 Gal’ & C-4 Gal”), 69.41 (C-3 Man), 69.48, 69.67 (C-
3 Man’ & C-3 Man”), 69.90, 69.97, 70.04 (C-5 Man, C-5 Man’ & C-5 Man”), 70.39, 
70.44, 70.46 (C-2 Gal, C-2 Gal’ & C-2 Gal”), 70.59 (br, C-2 Man’ & C-2 Man”), 70.92 
(C-2 Man), 71.81, 71.88, 71.96 (C-5 Gal, C-5 Gal’ & C-5 Gal”), 72.47, 72.58, 72.70 (C-3 
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Gal, C-3 Gal’ and C-3 Gal”), 72.96, 73.20 (C-4 Man’ & C-4 Man”), 73.96 (C-4 Man), 
93.94, 94.04 (2 x br, C-1 Man’ & C-1 Man”), 98.35 (C-1 Man), 101.03 (C-1 Gal’), 
101.22, 101.27 (C-1 Gal & C-1 Gal”), 128.24-133.15 (Ph), 165.02-167.78 (PhC=O) and 
173.58 (CH2CONH). 
31P NMR (CDCl3): δp -4.66, -4.42 (P & P’) and -0.59 (P”). 
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Methyl β-D-galactopyranosyl-(1→4)-α-D-mannopyranoside 6-(6-N-
biotinylaminohexyl phosphate), triethylammonium salt 50 
O
HO
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Hb (CH2)4C(O)NH(CH2)6O
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To a solution of compound 44 (82 mg, 0.055 mmol) in MeOH (20 ml) was added 
4.6M NaOMe in MeOH (200 µl), and the mixture was kept at rt for 20 h. Dowex 50W-
X4 (H+) resin was added to deionise the reaction mixture, then the resin was filtered 
off, and the filtrate was neutralised with trimethylamine. After concentration, water 
(5 x 10 ml) was evaporated off from the residue to remove methyl benzoate. This 
gave the biotinylated disaccharide monophosphate 50 (44.4 mg, 0.052 mmol, 95 %). 
1H NMR (D2O + C5D5N): δH 0.85-1.65 (21H, m, 3 x MeCH2 & 7 x CH2), 2.15 (2H, t, J 7.3, 
CH2CO), 2.70 (1H, d, Ja,b 12.9, H
b), 2.85 (1H, dd, Ja,c 4.7, H
a), 3.02 (1H, m, He), 3.09-
3.16 (8H, m, 3 x MeCH2 & CH2N), 3.30 (3H, s, OMe), 3.72 (1H, m, H-5), 3.88 (1H, dd, 
J2’,3’ 9.9, H-3’), 3.91-4.12 (9H, m, H-2, H-3, H-4, H-6a, H-6b, H-2’, H-5’ & CH2OP), 4.18 
(1H, dd, Jd,e 4.5, H
d), 4.20 (1H, d, J3’,4’ 3.4, H-4’), 4.30 (2H, m, H-6a’ & H-6b’), 4.45 (1H, 
m, Jc,d 8.0,  H
c), 4.65 (1H, d, J1’,2’ 7.9, H-1’) and 4.79 (1H, d, J1,2 1.4, H-1). 
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13C NMR (D2O + C5D5N): δc 7.83 (MeCH2), 24.50, 25.00, 25.67, 27.40, 27.78, 28.17 (6 x 
CH2), 29.65 (d, JC,P 7.8, CH2CH2OP), 35.11 (CH2CO), 38.73(CH2N), 39.45 (C
ab), 45.96 
(MeCH2), 54.06 (OMe), 55.03 (C
e), 59.56 (Cc), 60.09 (C-6), 61.35 (Cd), 64.07 (br, C-6’), 
65.41 (d, JC,P 5.5, CH2OP), 68.06 (C-4’), 69.13 (C-2), 69.38 (C-3), 70.69 (C-2’), 70.84 (C-
5), 72.60 (C-3’), 73.94 (d, JC,P 7.1, C-5’), 77.63 (C-4), 100.24 (C-1), 103.49 (C-1’), 
164.31 (NHCONH) and 174.63 (CH2CONH). 
31P NMR (D2O + C5D5N): δp -0.32. 
High resolution ES-MS(-): found m/z 760.2733 [M - Et3N - H]
- (C35H67N4O16PS requires 
M: 862.4010; C29H51N3O16PS
- requires m/z 760.2733). 
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Methyl β-D-galactopyranosyl-(1→4)-α-D-mannopyranoside 6-[β-D-
galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 6-(6-N-
biotinylaminohexyl phosphate)], bistriethylammonium salt 51 
O
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To a solution of compound 47 (57 mg, 0.022 mmol) in MeOH (15 ml) was added 
4.6M NaOMe in MeOH (150 µl), and the mixture was kept at rt for 20 h. Dowex 50W-
X4 (H+) resin was added to deionise the reaction mixture, then the resin was filtered 
off, and the filtrate was immediately neutralised with trimethylamine. After 
concentration, water (5 x 10 ml) was evaporated off from the residue to remove 
methyl benzoate. This gave the biotinylated tetrasaccharide diphosphate 51 (29.5 
mg, 0.0216 mmol, 98 %). 
1H NMR (D2O + C5D5N): δH 1.05-1.83 (14H, m, 7 x CH2), 1.34 (18H, t, 6 x MeCH2), 2.33 
(2H, t, J 7.2, CH2CO), 2.82 (1H, d, Ja,b 12.8, H
b), 2.95 (1H, dd, Ja,c 4.7, H
a), 3.12 (1H, m, 
He), 3.17-3.29 (14H, m, 6 x MeCH2 & CH2N), 3.32 (3H, s, OMe), 3.81 (1H, m, H-5 
Man), 4.02-4.09 (3H, m, H-3 Gal, H-5 Man’ & H-3 Gal’), 4.11-4.40 (18H, m, H-2, H-3, 
H-4, H-6a, H-6b Man, H-2, H-4, H-5, Gal, H-3, H-4, H-6a, H-6b Man’, H-2, H-4, H-5 
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Gal’, CH2OP & H
d), 4.45-4.58 (4H, m, H-6a H-6b Gal, H-2 Man’, H-6a H-6b Gal’ & Hc), 
4.82, 4.83 (2H, 2 x d, J1,2 7.8, J1,2 7.5, H-1 Gal & H-1 Gal’), 4.88 (1H, br, H-1 Man) and 
6.05 (1H, br d, J1,P 7.9, H-1 Man’), 
1H NMR (D2O) (for bis-ammonium salt of compound 51): δH 1.20-1.65 (14H, m, 7 x 
CH2), 2.14 (2H, t, J 7.2, CH2CO), 2.68 (1H, d, Ja,b 13.2, H
b), 2.89 (1H, dd, Ja,c 5.0, H
a), 
3.08 (2H, m, CH2N), 3.23 (1H, m, H
e), 3.30 (3H, s, OMe), 3.43, 3.45 (2H, 2 x dd, J2,3 
10.3, H-2 Gal & H-2 Gal’), 3.57 (2H, dd, J3,4 3.4, H-3 Gal & H-3 Gal’), 3.63 (1H, m, H-5 
Man), 3.88-3.97 (21H, m, H-2, H-3, H-4, H-6a, H-6b Man, H-4, H-5, H-6a, H-6b Gal, H-
2, H-3, H-4, H-5, H-6a H-6b Man’, H-4, H-5, H-6a, H-6b Gal’ & CH2OP), 4.31 (1H, dd, 
Jd,e 4.5, H
d), 4.34, 4.35 (2H, 2 x d, J1,2 7.9, H-1 Gal & H-1 Gal’), 4.50 (1H, dd, Jc,d 7.9, 
Hc), 4.66 (1H, d, J1,2 1.5, H-1 Man) and 5.33 (1H, dd, J1,P 7.7, J1,2 1.9, H-1 Man’). 
13C NMR (D2O + C5D5N): δc 7.80 (MeCH2), 24.48, 24.95, 25.65, 27.35, 27.73, 28.13 (6 x 
CH2), 29.62 (d, JC,P 7.3, CH2CH2OP), 35.07 (CH2CO), 38.71 (CH2N) 39.43 (C
ab), 45.90 
(MeCH2), 54.01 (OMe), 55.00 (C
e), 59.51 (Cc), 60.08, 60.12 (C-6 Man & C-6 Man’), 
61.30 (Cd), 63.77 (d, JC,P 4.0, C-6 Gal), 64.27 (d, JC,P 5.3, C-6 Gal’), 65.37 (d, JC,P 4.0, 
CH2OP), 67.95, 68.00 (C-4 Gal & C-4 Gal’), 68.71 (C-3 Man’), 69.04 (C-2 Man), 69.31 
(C-3 Man), 69.78 (d, JC,P 8.6, C-2 Man’), 70.64, 70.67 (C-2 Gal & C-2 Gal’), 70.79 (C-5 
Man), 72.16 (C-5 Man’), 72.46, 72.56 (C-3 Gal & C-3 Gal’), 73.80 (d, JC,P 7.9, C-5 Gal & 
C-5 Gal’), 77.26 (C-4 Man’), 77.52 (C-4 Man), 95.65 (d, JC,P 6.6 C-1 Man’), 100.17 (C-1 
Man), 103.38, 103.47 (C-1 Gal & C-1 Gal’), 164.32 (NHCONH) and 174.60 (CH2CONH). 
31P NMR (D2O + C5D5N): δp -2.33 (P) and 0.40 (P’). 
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High resolution ES-MS(-): found m/z 1164.3488 [M - 2Et3N - H]
- (C53H103N5O29P2S 
requires M: 1367.5935; C41H72N3O29P2S
- requires m/z 1164.3453). 
 
Methyl  β-D-galactopyranosyl-(1→4)-α-D-mannopyranoside 6-{β-D-
galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 6-[β-D-
galactopyranosyl-(1→4)-α-D-mannopyranosyl phosphate 6-(6-N-
biotinylaminohexyl phosphate)]}, tristriethylammonium salt 52 
O
HO
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To a solution of compound 49 (35 mg, 0.009 mmol) in MeOH (10 ml) was added 
4.6M NaOMe in MeOH (100 µl), and the mixture was kept at rt for 20 h. Dowex 50W-
X4 (H+) resin was added to deionise the reaction mixture, then the resin was filtered 
off, and the filtrate was immediately neutralised with trimethylamine. After 
concentration, water (5 x 10 ml) was evaporated off from the residue to remove 
methyl benzoate. This gave the biotinylated hexasaccharide triphosphate 52 (15.2 
mg, 0.0081 mmol, 90 %). 
1H NMR (D2O): δH 0.80-1.49 (14H, m, 7 x CH2), 1.50 (27H, t, 9 x MeCH2), 2.05 (2H, m, 
CH2CO), 2.29 (2H, m, H
a & Hb), 2.86-2.99 (21H, m, 9 x MeCH2, CH2N & H
e), 3.20 (3H, s, 
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OMe), 3.40-4.09 (40H, m, H-2, H-3, H-4, H-5, H-6a, H-6b Man, H-2, H-3, H-4, H-5, H-
6a, H-6b Gal, H-2, H-3, H-4, H-5, H-6a, H-6b Man’, H-2, H-3, H-4, H-5, H-6a, H-6b Gal’, 
H-2, H-3, H-4, H-5, H-6a, H-6b Man”, H-2, H-3, H-4, H-5, H-6a, H-6b Gal”, CH2OP, H
c & 
Hd), 4.39, 4.40, 4.41 (3H, 3 x d, J1,2 7.5, H-1 Gal, H-1 Gal’ & H-1 Gal”), 4.59 (1H, d, J1,2 
1.5, H-1 Man), 5.12 (1H, m, H-1 Man’ or Man”) and 5.48 (1H, m, H-1 Man’ or Man”). 
13C NMR (D2O) (selected signals): δc 8.04 (MeCH2), 39.62 (C
ab), 46.36 (MeCH2), 54.50 
(OMe), 59.83, 60.28 (C-6 Man, C-6 Man’ C-6 Man” & Cd), 62.43 (br, C-6 Gal, C-6 Gal’ 
& C-6 Gal”), 64.11 (br, CH2OP), 94.84 (br, C-1 Man’ & C-1 Man”), 94.41 (C-1 Man) and 
103.29, 104.23 (C-1 Gal, C-1 Gal’ & C-1 Gal”). 
31P NMR (D2O): δp -2.02 (P), 0.50 (P’) and 0.73 (P”). 
High resolution ES-MS(-): found m/z 1584.4125 [M - 3Et3N - H + NH3]
- 
(C71H139N6O42P3S requires M: 1872.7859; C53H96N4O42P3S
- requires m/z 1585.4438), 
1606.3834 [M - 3Et3N - 2H + K]
- (C53H92KN3O42P3S
- requires m/z 1606.3731), 
1628.3928 [M - 3Et3N - 3H + Na + K]
- (C53H91KN3NaO42P3S
- requires m/z 1628.3551), 
1633.9478 [M - 3Et3N - 4H + 3Na]
- (C53H90N3Na3O42P3S
- requires m/z 1634.3631) and 
1669.9165 [M - 2Et3N - H]
- (C59H108N4O42P3S
- requires m/z 1669.5377). 
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